Name: 2900-27-8|Boc-Phg-OH|98%
Brand: Ambeed
SKU: A242093
Price: 6.0 USD
Availability: InStock
Rating: 97 (29 reviews)

1
[ 24424-99-5 ]
[ 2935-35-5 ]
[ 2900-27-8 ]

Yield	Reaction Conditions	Operation in experiment
95%	With sodium hydroxide In 1,4-dioxane at 0 - 20℃; for 2h;
95%	With potassium carbonate In tetrahydrofuran; water at 20℃; for 18h;	2 Example 2 Preparation of N- -phenylglycinePhenylglycine Example 2 Preparation of N- -phenylglycinePhenylglycine (5.1 g, 33.76 mmol) is suspended in a 1 : 1 mixture of water and THF (50 ml) at room temperature and potassium carbonate (K2CO3, 1 1.66 g, 84,4 mmol) and Boc anhydride (7.36 g, 84.4 mmol) are added. The suspension is stirred at room temperature for 18 hours, controlling by LC-MS. The solids are removed by filtration and THF is evaporated under reduced pressvire. The remaining aqueous phase is acidified with a 2N HC1 aqueous solution and extracted two times with dichloromethane (40 ml each time). The organic phases are combined and dried on sodium sulphate. The suspension is filtered and the solvent is evaporated under reduced pressure. Petroleum ether is added during the evaporation to facilitate the precipitation. A white solid is obtained, which is filtered and dried to give 8.02 g of the title product (31.91 mmol; yield 95%). MS (ESI+): 252.2 ( +H4"), 525.3 (2M+Na) 1HNMR (400 MHz, DMSO): 12.75 (s, 1H, -OH), 7.55 (d, 1Η, -NH-Boc, J=8.4 Hz) 7.41-7.33 (m, 5H, Ph), 5.11 (d, 1H, Ha, J - 8.4 Hz), 1.39 (s, 9H, 3x -CH3).
94%	With sodium hydrogencarbonate In tetrahydrofuran; water at 20℃; for 21h;

90%	With sodium hydroxide In 1,4-dioxane for 14h;
90%	With potassium carbonate In methanol; water at 10 - 20℃;	2.1 (1) A mixture of (S)-2-amino-2-phenylacetic acid (100 g, 0.66 mol), potassium carbonate (109 g, 0.79 mol) was dissolved in water (1.0 L) and methanol (0.25 L), cooling to T <10 deg. C, di-tert-butyl dicarbonate (144 g, 0.66 mol) was added dropwise, room temperature reaction overnight, pH 4 to 5 with 1 N HCl, extraction with ethyl acetate (0.5 L * 3), saturated brine (0.5 L * 1) was washed, concentrated to give 150 g of a white solid, yield 90%.
89%	With sodium hydroxide In 1,4-dioxane
88.7%	Stage #1: (S)-2-phenylglycine With sodium hydroxide In 1,4-dioxane; water at 2.5℃; for 0.166667h; Stage #2: di-<i>tert</i>-butyl dicarbonate In 1,4-dioxane; water at 20℃; for 6h;	1-2 Example 1 In a 250ml four-neck flask, dissolve 4.53g (30mmol) of L-phenylglycine in 60ml of dioxane and 30ml of water, cool to 2.5±2.5, add 30ml of 1N NaOH solution, stir for 10 minutes and add 7.2g of BOC anhydride (33mmol), warm up to room temperature, and continue to stir for 6 hours. After the reaction is over, add 13% potassium hydrogen sulfate dilute solution to adjust the pH of the reaction solution to 2.0, add 50ml ethyl acetate, separate the layers, extract the aqueous phase with 30ml×2 ethyl acetate, combine the organic phases, wash with 50ml purified water, and anhydrous sulfuric acid Sodium is dry. Filter and evaporate the solvent under reduced pressure to dryness to obtain a colorless transparent viscous oil.Weigh, add 0.5% by weight of N-Boc-L-phenylglycine seed crystals (HPLC purity 99.3%) to this oil, let stand at room temperature for 24 hours, the oil is completely solidified and turned into a white solid, add 10 times the volume /Weight ether, beaten at room temperature for 2 hours, and filter. The product was obtained by drying under reduced pressure at 60°C for 15 hours. (Yield 88.7%, HPLC purity 99.1%).
87%	With sodium hydroxide In 1,4-dioxane; water at 20℃; Cooling with ice;
86%	With triethylamine In methanol; water at 25℃; for 8h;
86%	With triethylamine In methanol; water at 20℃; for 8h;
86%	With triethylamine In methanol; water at 20℃; for 8h;	1 Synthesis of: Compound (6) (S) -2 - ((t - t-butyl carbonyl) amino) -2-phenylacetic acid The L- phenylglycine (15.1g, 100mmol) placed in a reaction flask was added 200mL of methanol: water (3: 1), room temperatureStirring to dissolve, was added Et3N (15.1mL, 150mmol), the (Boc) 2O (32.7g, 150mmol) was added dropwise to the reaction mixture, followed by stirring at room temperature for 8 hours, the solvent is removed by rotary evaporation, dissolved in 100mL of citric acid, with acetic acid ethyl ester (3 × 50mL) and extracted with anhydrous sodium sulfate, crude did spin with hexane to give product 6 (21.8g, 86% yield).
82%	With sodium hydroxide In <i>tert</i>-butyl alcohol at 20℃; for 1h;	24.1 Step 1: (S)-2-((tert-butoxycarbonyl)amino)-2-phenylacetic acid To a solution of (S)-2-amino-2-phenylacetic acid (3.0 g, 19.8 mmol) in 1 M sodium hydroxide solution (28 mL) was added a solution of di-tert-butyl dicarbonate (4.75 g, 21.78 mmol) in tert-butyl alcohol (16 mL). The resulting suspension was stirred at roomtemperature for 1 h. The volatile solvent was removed under reduced pressure and the pH of the remaining solution was adjusted with citric acid to 3. The solid was filtered and dried to give (S)-2-((tert-butoxycarbonyl)amino)-2-phenylacetic acid (4.1 g, 16.3 mmol, 82 % yield). LCMS (2.5 min formic acid): Rt = 1.48 min, [M+H]+= 273.9.
60%	With triethylamine In methanol; water for 6h;
	With sodium hydroxide In 1,4-dioxane for 18h; Ambient temperature;
	With sodium hydroxide In <i>tert</i>-butyl alcohol
	With sodium hydroxide In tetrahydrofuran; water at 20℃;
	With sodium hydroxide In 1,4-dioxane at 20℃;
	With sodium hydrogencarbonate In tetrahydrofuran at 23℃; for 12h;
	With sodium hydroxide In tetrahydrofuran at 20℃; for 18h;
	Stage #1: (S)-2-phenylglycine With potassium carbonate In water at 100℃; for 2h; Stage #2: di-<i>tert</i>-butyl dicarbonate In 1,4-dioxane at 20℃; for 24h; Further stages.;
	With tert-butylimino-tris(dimethylamino)phosphorane In acetonitrile at 20℃; for 16h;
	With triethylamine In tetrahydrofuran; water at 20℃;
	With triethylamine In N,N-dimethyl-formamide	General Procedure: Compounds 1-15 were synthesized by standard solution phase peptide synthesis by which sequential elongation and coupling of an amine to a carboxylic acid was performed in DMF with benzotriazol-1-yl-oxytris-(dimethylamino)phosphonium hexafluorophosphate (BOP) or N,N'-carbonyldiimidazole (CDI) as coupling reagent and Et3N as base. Although BOP was favored over CDI for coupling to the P'1 residue, CDI showed higher coupling reactivity with bulky amines. Peptide coupling to the P1 residue was accomplished using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) and 1-hydroxybenzotriazole (HOBt) as additive, without a base, to avoid reported side-reactions. Attachment of a Boc protection group to an amino group was achieved with Boc2O and Et3N in DMF, while the removal of the Boc protection group was achieved with 4 N HCl in dioxane. The hydroxyl group in compounds 2 and 9 was acetyl protected with acetic anhydride in pyridine, and eventually removed by a 50% v/v mixture of 4 N NaOH(aq) and MeOH. The N-terminal cap was appended in DMF and Et3N as base by a reaction with methyl chloroformate for compounds 2 and 3, or with benzylbromide for compound 13. The nucleophilic substitution reactions in compounds 11, 12, 14 and 15 was performed with methyl iodide or ethyl iodide, respectively, to afford a mixture of mono- and disubstituted products. After preparative HPLC purification, all target compounds (1-15) were >95% pure by analytical HPLC. The identities of the compounds were confirmed by TOF MS and ESI-Q MS.
	With sodium hydroxide In methanol
	Stage #1: (S)-2-phenylglycine With sodium hydroxide In 1,4-dioxane; water for 0.0833333h; Cooling with ice; Stage #2: di-<i>tert</i>-butyl dicarbonate With sodium hydrogencarbonate In 1,4-dioxane; water at 20℃; for 18h;
	With triethylamine In methanol; water
	With sodium hydroxide In tetrahydrofuran; water at 20℃; for 4h;	General Procedure for the Synthesis of Compounds 6a-d General procedure: Amino acid derivative (5 mmol) was dissolved in a mixture of tetrahydrofuran (50 mL) and water (20 mL). A 1 N NaOH (6 mL) was added followed by the addition of 1.1 g di-tert-butyl dicarbonate (5mmol) dropwise at room temperature. After stirring for 4 h, the tetrahydrofuran was evaporated under vacuum from the reaction mixture. To the residue was added ethyl acetate (50 mL) and 5% citric acid (30 mL). The organic layer was separated, washed with water (20 mL × 3), dried with anhydrous MgSO4 and rotary evaporated to dryness. The crude residue was used the next reaction without purification. A mixture of the above N-Boc protected amino acids (2.2 mmol), compound 4 (0.98 g, 2 mmol), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (0.42 g,2.2 mmol), 1-hydroxybenzotriazole (0.30 g, 2.2 mmol), triethylamine (0.30 g, 3.0 mmol) and dichloromethane (50 mL) was stirred at room temperature for 36 h. The mixture was washed with saturated aqueous NaHCO3 and water then, evaporated under vacuum and the residue was treated with a mixture of trifluoroacetic acid (TFA, 10 mL) and dichloromethane (10 mL) at room temperature for 30 min. The reaction mixture was quenched with 25% aqueous NaHCO3 (30 mL) and washed with water, dried with anhydrous Na2SO4 overnight and rotary evaporated to dryness. The crude residue thus obtained was purified by silica gel column chromatography (petroleum ether-ethyl acetate 1:2 v/v) to afford the desired compounds.
	With sodium hydroxide In tetrahydrofuran at 0 - 20℃; for 3h;	1 Step 1: (S)-2-((terf-butoxycarbonyl)amino)-2-phenylacetic acid At 0°C, to a solution of (S)-2-amino-2-phenylacetic acid (3.0 g, 19.9 mmol) in THF (20 mL) were added 10% NaOH solution (20 mL, 50 mmol) and Boc20 (4.8 g, 22 mmol) and the contents were stirred at ambient temperature. After 3 hr, the reaction mixture was cooled to 0°C and was acidified carefully with 50% citric acid solution (10 mL) until the pH of the solution is 4. The organic contents were extracted with EtOAc (3x25 mL) and the combined organic extracts were washed with brine (1x20 mL), dried over Na2S04, concentrated to afford (S)-2- ((tert-butoxycarbonyl)amino)-2-phenylacetic acid. The residue thus obtained was taken directly for step 2 without further purification. MS ESI calc'd. for Ci3Hi8N04 [M+l]+ 252, found 252.2.
	With sodium hydroxide In 1,4-dioxane; water at 0 - 20℃; for 1h;
	With sodium hydroxide
	With sodium hydroxide In water; <i>tert</i>-butyl alcohol
	Stage #1: (S)-2-phenylglycine With sodium hydroxide In water; <i>tert</i>-butyl alcohol at 20℃; for 0.25h; Stage #2: di-<i>tert</i>-butyl dicarbonate In water; <i>tert</i>-butyl alcohol
	With sodium hydrogencarbonate; sodium hydroxide In 1,4-dioxane; water at 25℃; Cooling with ice;
	With triethylamine In methanol at 20℃; for 16h;
	With sodium hydroxide In water; <i>tert</i>-butyl alcohol at 20℃; for 1h;	Step 1: (S)-2-((tert-butoxycarbonyl)amino)-2-phenylacetic acid (115a). A solution of (S)-2-amino-2-phenylacetic acid 114a (1.0 g, 6.6 mmol) in NaOH (1 M aqueous solution, 1.4 mL) was treated with a solution of Boc2O (1.68 mL, 7.34 mmol) in tBuOH (1.4 mL). The resulting suspension was stirred at rt for 1 h. After completion, the solvent was removed under reduced pressure and the pH of the remaining solution was adjusted to 3 with 4 M aq. HCl solution. The resulting suspension was diluted with CHCl3 (2 mL), the layers were separated, and the aqueous solution was extracted with CHCl3 (2 × 1 mL). The combined organic solution was dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude product (1.56 g, 93%, white powder) was used in the next step without further purification. LCMS (ES+) m/z calculated for C13H17NO4 251.12, found 152 (M+H-Boc)+.
	With sodium hydroxide In water; <i>tert</i>-butyl alcohol at 20℃; for 1h;	Step 1: (S)-2-((tert-butoxycarbonyl)amino)-2-phenylacetic acid (115a). A solution of (S)-2-amino-2-phenylacetic acid 114a (1.0 g, 6.6 mmol) in NaOH (1 M aqueous solution, 1.4 mL) was treated with a solution of Boc2O (1.68 mL, 7.34 mmol) in tBuOH (1.4 mL). The resulting suspension was stirred at rt for 1 h. After completion, the solvent was removed under reduced pressure and the pH of the remaining solution was adjusted to 3 with 4 M aq. HCl solution. The resulting suspension was diluted with CHCl3 (2 mL), the layers were separated, and the aqueous solution was extracted with CHCl3 (2 × 1 mL). The combined organic solution was dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude product (1.56 g, 93%, white powder) was used in the next step without further purification. LCMS (ES+) m/z calculated for C13H17NO4 251.12, found 152 (M+H-Boc)+.

Reference： [1]Bodas, Mandar S.; Upadhyay, Puspesh K.; Kumar, Pradeep [Tetrahedron Letters, 2004, vol. 45, # 5, p. 987 - 988]
[2]Current Patent Assignee: P&R SPA - WO2015/92502, 2015, A1 Location in patent: Page/Page column 6; 7
[3]Pearson, Anthony J.; Chelliah, Mariappan V. [Journal of Organic Chemistry, 1998, vol. 63, # 9, p. 3087 - 3098]
[4]Yan, Shunqi; Appleby, Todd; Larson, Gary; Wu, Jim Z.; Hamatake, Robert K.; Hong, Zhi; Yao, Nanhua [Bioorganic and Medicinal Chemistry Letters, 2007, vol. 17, # 7, p. 1991 - 1995]
[5]Current Patent Assignee: ASTATECH CHENGDU BIOPHARM - CN104592163, 2016, B Location in patent: Paragraph 0050; 0051
[6]Anslow, Amberley. S.; Harwood, Laurence. M.; Lilley, Ian. A. [Tetrahedron Asymmetry, 1995, vol. 6, # 10, p. 2465 - 2468]
[7]Current Patent Assignee: SHANDONG JINCHENG COURAGE CHEMICAL - CN112661672, 2021, A Location in patent: Paragraph 0030-0038
[8]Location in patent: experimental part Guha, Samit; Chakraborty, Tushar; Banerjee, Arindam [Green Chemistry, 2009, vol. 11, # 8, p. 1139 - 1145]
[9]Zhang, Lei; Zhang, Yingjie; Chou, C. James; Inks, Elizabeth S.; Wang, Xuejian; Li, Xiaoguang; Hou, Jinning; Xu, Wenfang [ChemMedChem, 2014, vol. 9, # 3, p. 638 - 648]
[10]Zhang, Lei; Wang, Xuejian; Li, Xiaoguang; Xu, Wenfang [Journal of Enzyme Inhibition and Medicinal Chemistry, 2014, vol. 29, # 3, p. 333 - 337]
[11]Current Patent Assignee: SHANDONG UNIVERSITY - CN105481736, 2016, A Location in patent: Paragraph 0039; 0103; 0104
[12]Current Patent Assignee: UNIVERSITY OF NORTH CAROLINA SYSTEM; GLAXOSMITHKLINE PLC - WO2020/110056, 2020, A1 Location in patent: Page/Page column 194
[13]Hendrix; Roets; Bervoets; Thomas; Pijcke; Busson; Janssen; Hoogmartens [Archiv der Pharmazie, 1994, vol. 327, # 4, p. 215 - 219]
[14]Dondoni; Perrone [Synthesis, 1993, # 11, p. 1162 - 1176]
[15]Lee, Kee-Young; Kim, Yong-Hyun; Park, Min-Sung; Ham, Won-Hun [Tetrahedron Letters, 1998, vol. 39, # 44, p. 8129 - 8132]
[16]Pastor, Isidro M; Adolfsson, Hans [Tetrahedron Letters, 2002, vol. 43, # 9, p. 1743 - 1746]
[17]Catalano, John G; Deaton, David N; Furfine, Eric S; Hassell, Annie M; McFadyen, Robert B; Miller, Aaron B; Miller, Larry R; Shewchuk, Lisa M; Willard Jr., Derril H; Wright, Lois L [Bioorganic and medicinal chemistry letters, 2004, vol. 14, # 1, p. 275 - 278]
[18]Nicolaou; Hughes, Robert; Pfefferkorn, Jeffrey A.; Barluenga, Sofia; Roecker [Chemistry - A European Journal, 2001, vol. 7, # 19, p. 4280 - 4295]
[19]Pastor, Isidro M.; Vaestilae, Patrik; Adolfsson, Hans [Chemistry - A European Journal, 2003, vol. 9, # 17, p. 4031 - 4045]
[20]Yokoyama; Hikawa; Murakami [Journal of the Chemical Society. Perkin Transactions 1 (2001), 2001, # 12, p. 1431 - 1434]
[21]Palomo, Claudio; Palomo, Antonio L; Palomo, Francisco; Mielgo, Antonia [Organic letters, 2002, vol. 4, # 23, p. 4005 - 4008]
[22]Location in patent: scheme or table Nguyen, Jeffrey-Tri; Kato, Keiko; Kumada, Henri-Obadja; Hidaka, Koushi; Kimura, Tooru; Kiso, Yoshiaki [Bioorganic and Medicinal Chemistry Letters, 2011, vol. 21, # 6, p. 1832 - 1837]
[23]Nguyen, Jeffrey-Tri; Kato, Keiko; Hidaka, Koushi; Kumada, Henri-Obadja; Kimura, Tooru; Kiso, Yoshiaki [Bioorganic and Medicinal Chemistry Letters, 2011, vol. 21, # 8, p. 2425 - 2429]
[24]Pan, Huili; Yang, Kanghui; Zhang, Jian; Xu, Yingying; Jiang, Yuqi; Yuan, Yumei; Zhang, Xiaopan; Xu, Wenfang [Journal of Enzyme Inhibition and Medicinal Chemistry, 2013, vol. 28, # 4, p. 717 - 726]
[25]Zhao, Wenjun; Huang, Li; Guan, Yong; Wulff, William D. [Angewandte Chemie - International Edition, 2014, vol. 53, # 13, p. 3436 - 3441][Angew. Chem., 2014, vol. 126, # 13, p. 3504 - 3509,6]
[26]Zhang, Lei; Wang, Xuejian; Li, Xiaoguang; Zhang, Lihui; Xu, Wenfang [Journal of Enzyme Inhibition and Medicinal Chemistry, 2014, vol. 29, # 4, p. 582 - 589] Li, Jingyao; Li, Xiaoyang; Wang, Xue; Hou, Jinning; Zang, Jie; Gao, Shuai; Xu, Wenfang; Zhang, Yingjie [Chemical Biology and Drug Design, 2016, p. 574 - 584] Zhang, Lei; Zhang, Li; Bian, Jiang; Jiang, Qixiao; Gao, Jianjun; Song, Weiguo [Anti-Cancer Drugs, 2018, vol. 29, # 2, p. 145 - 156]
[27]Shang, Ruo-Feng; Wang, Guan-Hua; Xu, Xi-Ming; Liu, Si-Jie; Zhang, Chao; Yi, Yun-Peng; Liang, Jian-Ping; Liu, Yu [Molecules, 2014, vol. 19, # 11, p. 19050 - 19065]
[28]Current Patent Assignee: MERCK & CO INC - WO2015/94929, 2015, A1 Location in patent: Page/Page column 72
[29]Kim, Jeongho; Ko, Kwangwook; Cho, Seung Hwan [Angewandte Chemie - International Edition, 2017, vol. 56, # 38, p. 11584 - 11588][Angew. Chem., 2017, vol. 129, # 38, p. 11742 - 11746]
[30]Feng, Lei; Gao, Guangpeng; Zhao, Hongmei; Zheng, Li; Wang, Yu; Stavropoulos, Pericles; Ai, Lin; Zhang, Jiaxin [Journal of Organic Chemistry, 2018, vol. 83, # 22, p. 13874 - 13887]
[31]Kapoor, Mohit; Chand-Thakuri, Pratibha; Young, Michael C. [Journal of the American Chemical Society, 2019, vol. 141, # 19, p. 7980 - 7989]
[32]Chand-Thakuri, Pratibha; Landge, Vinod G.; Kapoor, Mohit; Young, Michael C. [Journal of Organic Chemistry, 2020, vol. 85, # 10, p. 6626 - 6644]
[33]Chen, Ying-Chun; Du, Wei; Song, Xue; Yan, Ru-Jie [Organic Letters, 2020, vol. 22, # 19, p. 7617 - 7621]
[34]Cockram, Peter E.; Turner, Callum A.; Slawin, Alexandra M. Z.; Smith, Terry K. [ChemMedChem, 2022, vol. 17, # 4]
[35]Abate, Luigi; Amaudrut, Jerome; Beghetto, Elisa; Bianchi, Elisabetta; Bresciani, Alberto; Colarusso, Stefania; Conte, Immacolata; Ferrigno, Federica; Missineo, Antonino; Montalbetti, Christian; Ontoria, Jesus M.; Paonessa, Giacomo; Pavone, Francesca; Ponzi, Simona; Tomei, Licia; Toniatti, Carlo [Bioorganic and Medicinal Chemistry, 2022, vol. 57]
[36]Abate, Luigi; Amaudrut, Jerome; Beghetto, Elisa; Bianchi, Elisabetta; Bresciani, Alberto; Colarusso, Stefania; Conte, Immacolata; Ferrigno, Federica; Missineo, Antonino; Montalbetti, Christian; Ontoria, Jesus M.; Paonessa, Giacomo; Pavone, Francesca; Ponzi, Simona; Tomei, Licia; Toniatti, Carlo [Bioorganic and Medicinal Chemistry, 2022, vol. 57]

2
[ 2900-27-8 ]
[ 543-27-1 ]
[ 63398-31-2 ]

Yield	Reaction Conditions	Operation in experiment
	With 4-methyl-morpholine In tetrahydrofuran at -20℃; for 0.166667h;
	With triethylamine
	With N-methylmorpholinepolystyrene In tetrahydrofuran at -20℃; for 2h;

	With triethylamine In dichloromethane at 0℃; for 0.333333h;
	With 4-methyl-morpholine In tetrahydrofuran at -15℃; for 0.75h;
	With 4-methyl-morpholine In tetrahydrofuran at -15℃;
	In dichloromethane at 0℃; Inert atmosphere;
	With 4-methyl-morpholine In tetrahydrofuran at -15℃; for 0.75h; Inert atmosphere;
	With 4-methyl-morpholine In tetrahydrofuran; dichloromethane at -15℃; for 1h; Inert atmosphere;	Amino acid coupling reaction-general procedure General procedure: A stirred solution of N-α-protected amino acids 1a-f (10.58 mmol) and N-methylmorpholine (11.66 mmol) in anhydrous THF (16 mL) was cooled to -15 °C under nitrogen atmosphere, before the very slow addition of isobutyl chloroformate (11.86 mmol) in anhydrous DCM (5.3 mL). After 1 h of stirring, a solution of N-benzyl-tert-butyl-β-aminoesters 2 (10.58 mmol) and N-methylmorpholine (12.65 mmol) in anhydrous DCM was added slowly. The mixture was stirred for two additional hours at -15 °C and then was allowed to warm to room temperature, and stirring was continued for 18 h. The solvent was removed under vacuum and ethyl acetate (30 mL) was added to the residue. The resulting solution was washed sequentially with water, 1 N HCl, water, saturated solution of NaHCO3, and water. The organic layer was separated, dried over anhydrous Na2SO4, filtered, and concentrated under vacuum. In order to have a complete analysis of the physical and spectroscopic properties of the chiral dipeptides it was decided to prepare both enantiomers and also the racemic mixture to serve as chiral HPLC standards.

Reference： [1]Johnson, Rodney L.; Bontems, Roger J.; Yang, Kaipeen E.; Mishra, Ram K. [Journal of Medicinal Chemistry, 1990, vol. 33, # 6, p. 1828 - 1832]
[2]Tsuda, Yuko; Wanaka, Keiko; Tada, Mayako; Okamoto, Shosuke; Hijikata-Okunomiya, Akiko; Okada, Yoshio [Chemical and Pharmaceutical Bulletin, 1998, vol. 46, # 3, p. 452 - 457]
[3]Jung, Jae-Chul; Avery, Mitchell A. [Tetrahedron Letters, 2006, vol. 47, # 45, p. 7969 - 7972]
[4]Liu, Yanling; Liu, Xiaohua; Xin, Junguo; Feng, Xiaoming [Synlett, 2006, # 7, p. 1085 - 1089]
[5]Pastor, Isidro M.; Vaestilae, Patrik; Adolfsson, Hans [Chemistry - A European Journal, 2003, vol. 9, # 17, p. 4031 - 4045]
[6]Bogevig, Anders; Pastor, Isidro M.; Adolfsson, Hans [Chemistry - A European Journal, 2004, vol. 10, # 1, p. 294 - 302]
[7]Location in patent: scheme or table Rix, Diane; Labat, Stephane; Toupet, Loic; Crevisy, Christophe; Mauduit, Marc [European Journal of Inorganic Chemistry, 2009, # 13 SPEC. ISS., p. 1989 - 1999]
[8]Coll, Mercedes; Pamies, Oscar; Adolfsson, Hans; Dieguez, Montserrat [Chemical Communications, 2011, vol. 47, # 44, p. 12188 - 12190]
[9]Jimenez-Gonzalez, Erika; Gabriela Avila-Ortiz, C.; Gonzalez-Olvera, Rodrigo; Vargas-Caporali, Jorge; Juaristi, Eusebio; Dewynter, Georges [Tetrahedron, 2012, vol. 68, # 47, p. 9842 - 9852,11]

3
[ 2900-27-8 ]
[ 541-41-3 ]
C₁₆H₂₁NO₆ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With triethylamine In tetrahydrofuran at -15℃; for 0.25h;
	With 4-methyl-morpholine In tetrahydrofuran at -20 - -5℃;
	With 4-methyl-morpholine In tetrahydrofuran at -10℃; for 0.166667h;

	With 4-methyl-morpholine In dichloromethane at 0℃; for 0.166667h;
	With triethylamine In tetrahydrofuran at 0℃; for 0.666667h; Inert atmosphere;	4.3. General procedure for the amide 5 General procedure: To a solution of N-Boc-amino acid 3 (63.5 mmol) in THF (100 mL) at 0 °C were added triethylamine (63.5 mmol) and ethyl chloroformate (63.5 mmol) over a period of ca. 10 min, and the reaction mixture was stired for 30 min. After the addition of the 2-aminobenzamide 4 (95.25 mmol), the mixture was stirred for an additional 1 h at 0 °C. Then, the reaction mixture was warmed to room temperature, and kept stirring overnight. After the solvent was evaporated under reduced pressure, the residue was dissolved in EtOAc (150 mL) and washed with 3 M HCl (2 × 100 mL), and brine (100 mL). The organic layer was dried over Na2SO4 and the solvent was evaporated under reduced pressure (20 mbar, 20 °C). Crystallization of crude mixture gave the corresponding amide 5.

Reference： [1]Podlech, Joachim; Seebach, Dieter [Liebigs Annalen, 1995, # 7, p. 1217 - 1228]
[2]Sureshbabu, Vommina Venkata; Narendra; Kantharaju [Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2008, vol. 47, # 6, p. 920 - 926]
[3]Chennakrishnareddy, Gundala; Nagendra, Govindappa; Hemantha, Hosahalli P.; Das, Ushati; Guru Row, Tayur N.; Sureshbabu, Vommina V. [Tetrahedron, 2010, vol. 66, # 34, p. 6718 - 6724]
[4]Selvakumar, Sermadurai; Sivasankaran, Dhanasekaran; Singh, Vinod K. [Organic and Biomolecular Chemistry, 2009, vol. 7, # 15, p. 3156 - 3162]
[5]Location in patent: experimental part Cakici, Murat; Catir, Mustafa; Karabuga, Semistan; Ulukanli, Sabri; Kilic, Hamdullah [Tetrahedron Asymmetry, 2011, vol. 22, # 3, p. 300 - 308]

4
[ 2900-27-8 ]
[ 6638-79-5 ]
[ 216769-51-6 ]

Yield	Reaction Conditions	Operation in experiment
95%	With triethylamine; dicyclohexyl-carbodiimide In chloroform at 0℃; for 1h; Inert atmosphere;
	With benzotriazol-1-ol; triethylamine; dicyclohexyl-carbodiimide In dichloromethane Yield given;
	With O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate; N-ethyl-N,N-diisopropylamine In acetonitrile at 0 - 20℃;

	With 1,1'-carbonyldiimidazole In dichloromethane
	With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine In dichloromethane at 20℃; for 2h;	2 Step 2: (S)-terf-butyl (2-(methoxy(methyl)amino)-2-oxo-l-phenylethyl)carbamate To a solution of (S)-2-((fert-butoxycarbonyl)amino)-2-phenylacetic acid (1.0 g, 4.0 mmol) in dichloromethane (10 mL) were added Ν,Ο-dimethyl hydroxylamine hydrochloride (0.77 g, 8.0 mmol), EDCI (1.2 g, 6.0 mmol), HOBt (0.05 g, 0.4 mmol), Et3N (0.8 g, 8.0 mmol) and the contents were stirred at ambient temperature. After 2 hr, the reaction was quenched with ice cold H20 (10 mL), and the organic contents were extracted with CH2C12 (2x30 mL). The combined organic extracts were washed with brine (1x20 mL), dried over Na2S04, concentrated and the residue thus obtained was purified by flash column chromatography to afford (S)-tert- butyl (2-(methoxy(methyl)amino)-2-oxo-l-phenylethyl)carbamate. 1H NMR (300MHz , CDC13) δ 7.39-7.29 (m, 5H), 5.77 (bs, 1H), 5.73 (bs, 1H), 3.47 (s, 3H), 3.20 (s, 3H), 1.42 (s, 9H).
	With triethylamine; dicyclohexyl-carbodiimide In chloroform at 0 - 20℃; for 1h;
2.85 g	Stage #1: (2S)-2-[(tert-butoxycarbonyl)amino]-2-phenylethanoic acid With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane for 0.166667h; Stage #2: N,O-dimethylhydroxylamine*hydrochloride In dichloromethane for 16h;

Reference： [1]Location in patent: experimental part Ghorai, Manas K.; Kumar, Amit; Tiwari, Deo Prakash [Journal of Organic Chemistry, 2010, vol. 75, # 1, p. 137 - 151]
[2]Lee, Kee-Young; Kim, Yong-Hyun; Park, Min-Sung; Ham, Won-Hun [Tetrahedron Letters, 1998, vol. 39, # 44, p. 8129 - 8132]
[3]Hein, Jason E.; Geary, Laina M.; Jaworski, Ashley A.; Hultin, Philip G. [Journal of Organic Chemistry, 2005, vol. 70, # 24, p. 9940 - 9946]
[4]Morwick, Tina; Hrapchak, Matt; DeTuri, Molly; Campbell, Scot [Organic Letters, 2002, vol. 4, # 16, p. 2665 - 2668]
[5]Current Patent Assignee: MERCK & CO INC - WO2015/94929, 2015, A1 Location in patent: Page/Page column 72
[6]Kim, Jeongho; Ko, Kwangwook; Cho, Seung Hwan [Angewandte Chemie - International Edition, 2017, vol. 56, # 38, p. 11584 - 11588][Angew. Chem., 2017, vol. 129, # 38, p. 11742 - 11746]
[7]Cockram, Peter E.; Turner, Callum A.; Slawin, Alexandra M. Z.; Smith, Terry K. [ChemMedChem, 2022, vol. 17, # 4]

5
[ 13836-37-8 ]
[ 2900-27-8 ]
[ 42294-64-4 ]
[ 47355-10-2 ]
Boc-His(N^im-Tos), Boc-Glu(γ-OBzl), Boc-Nle, Boc-Gly, N-acetylimidazol [ No CAS ]
Ac-4. Pgl⁷>-α-MSH_4-11-NH2 [ No CAS ]

Reference： [1]Collection of Czechoslovak Chemical Communications,1988,vol. 53,p. 2549 - 2573

6
[ 2900-27-8 ]
[ 143978-92-1 ]

Yield	Reaction Conditions	Operation in experiment
99%	Stage #1: (2S)-2-[(tert-butoxycarbonyl)amino]-2-phenylethanoic acid With ammonium hydroxide; benzotriazol-1-ol In N,N-dimethyl-formamide at 0℃; for 0.166667h; Stage #2: With 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In N,N-dimethyl-formamide at 25℃; for 18h;	61.A To a solution of (S)-2-(tert-butoxycarbonylamino)-2-phenylacetic acid (1.00 g, 3.98 mmol) in DMF (5 mL) and was added ammonium hydroxide (2.0 mL, excess), and HOBt (645 mg, 4.78 mmol) and the resulting solution stirred at 0° C. for 10 minutes. EDCI (916 mg, 4.78 mmol) was added and the reaction stirred at 25° C. for 18 hours. The mixture was concentrated in vacuo, the resulting residue was diluted with ethyl acetate (45 mL), brine (10 mL), and 5% H3PO4 aqueous solution (10 mL), and the layers were separated. The organic layer was washed with 5% H3PO4 aqueous solution (10 mL), twice with saturated aqueous sodium bicarbonate solution (15 mL), water (15 mL), and brine (15 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated in vacuo to afford the title compound as a light colored solid. The crude material was taken on directly to the next step. (0.990 g, 99% yield) MS (ESI+) m/z=251 (M+H)+
	Stage #1: (2S)-2-[(tert-butoxycarbonyl)amino]-2-phenylethanoic acid With benzotriazol-1-ol; N-(3-dimethylaminopropyl)-N-ethylcarbodiimide In N,N-dimethyl-formamide at 0℃; for 0.25h; Stage #2: With ammonium hydroxide In N,N-dimethyl-formamide Further stages.;
	Stage #1: (2S)-2-[(tert-butoxycarbonyl)amino]-2-phenylethanoic acid With 4-methyl-morpholine; chloroformic acid ethyl ester In tetrahydrofuran at -10℃; for 0.333333h; Stage #2: With ammonia In tetrahydrofuran; water at -10℃;

Reference： [1]Current Patent Assignee: ABBVIE INC - US2010/29686, 2010, A1 Location in patent: Page/Page column 75
[2]Ward, Yancey D.; Thomson, David S.; Frye, Leah L.; Cywin, Charles L.; Morwick, Tina; Emmanuel, Michel J.; Zindell, Renée; McNeil, Daniel; Bekkali, Younes; Giradot, Marc; Hrapchak, Matt; DeTuri, Molly; Crane, Kathy; White, Della; Pav, Susan; Wang, Yong; Hao, Ming-Hong; Grygon, Christine A.; Labadia, Mark E.; Freeman, Dorothy M.; Davidson, Walter; Hopkins, Jerry L.; Brown, Maryanne L.; Spero, Denice M. [Journal of Medicinal Chemistry, 2002, vol. 45, # 25, p. 5471 - 5482]
[3]Location in patent: experimental part Sureshbabu, Vommina V.; Naik, Shankar A.; Nagendra [Synthetic Communications, 2009, vol. 39, # 3, p. 395 - 406]

7
[ 2900-27-8 ]
[ 100-39-0 ]
(S)-benzyl 2-[(tert-butoxycarbonyl)amino]-2-phenylacetate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
95%	With potassium carbonate In N,N-dimethyl-formamide at 20℃; for 79h; Inert atmosphere;	R.44 (S)-Benzyl 2-[(tert-butoxycarbonyl)amino]-2-phenylacetate To a solution of 2.50 g (9.95 mmol) of (S)-2-[(tert-butoxycarbonyl)amino]-2-phenylacetic acid in 30 ml of DMF, 1.47 g (10.6 mmol) of potassium carbonate was dividedly added with stirring at room temperature in a nitrogen atmosphere, and subsequently, 1.20 ml (10.1 mmol) of benzyl bromide was added dropwise at room temperature, stirred at the same temperature as above for 7 hours, and then left at room temperature for 3 days. After the completion of the reaction, toluene was added to the reaction solution and washed with water twice. All of the obtained organic layers were washed with a saturated aqueous solution of sodium chloride, then dried over anhydrous magnesium sulfate, filtered, and then concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (elution solvent: n-hexane:ethyl acetate = 100:0 to 79:21 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure to obtain 3.24 g of the title compound (yield: 95%) as a white solid. Mass spectrum (CI, m/z): 342 [M+1]+. 1H-NMR spectrum (400 MHz, CDCl3) δ: 7.37 - 7.27 (m, 8H), 7.23 - 7.15 (m, 2H), 5.61 - 5.50 (m, 1H), 5.40 - 5.33 (m, 1H), 5.23 - 5.08 (m, 2H), 1.49 - 1.29 (m, 9H).
	In acetonitrile at 20℃; for 6h;

Reference： [1]Current Patent Assignee: UBE INDUSTRIES LIMITED - EP3214086, 2017, A1 Location in patent: Paragraph 0811-0813
[2]Palomo, Claudio; Palomo, Antonio L; Palomo, Francisco; Mielgo, Antonia [Organic letters, 2002, vol. 4, # 23, p. 4005 - 4008]

8
[ 1139-83-9 ]
[ 2900-27-8 ]
3-O-(N-(t-butoxycarbonyl)phenylglycyl)-7,8,9,10-tetrahydro-6H-dibenzo[b,d]pyran-6-one [ No CAS ]

Reference： [1]Chemistry of Natural Compounds,2002,vol. 38,p. 416 - 423

9
[ 2900-27-8 ]
(S)-Nα-(tert-butoxycarbonyl)phenylglycine hydroxamic acid [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
90%	With 4-methyl-morpholine; 1,3,5-trichloro-2,4,6-triazine; hydroxylamine hydrochloride In dichloromethane at 0 - 20℃;
68%	Stage #1: (2S)-2-[(tert-butoxycarbonyl)amino]-2-phenylethanoic acid With dmap; ethyl 2-(tert-butoxycarbonyloxyimino)-2-cyanoacetate; N-ethyl-N,N-diisopropylamine In tetrahydrofuran at 0 - 5℃; for 0.5h; Stage #2: With hydroxylamine hydrochloride In tetrahydrofuran; N,N-dimethyl-formamide at 20℃; for 2h;	General procedure for the synthesis of hydroxamic acids General procedure: Ethyl 2-(tertbutoxycarbonyloxyimino)-2-cyanoacetate (Boc-Oxyma, I) (1 mmol) wasadded to a stirred solution of carboxylic acid (1 mmol), DIPEA (1 mmol), andDMAP (0.1 mmol) in THF (2 mL) at 0-5 C. Then the reaction mixture wasstirred for 30 min followed by the addition of hydroxylamine hydrochloride inDMF (0.5 mL), DIPEA (1.5 mmol). The progress of the reaction was monitoredby TLC at room temperature. After completion of the reaction, the reactionmixture was concentrated using rotary evaporator and then diluted with15 mL of ethyl acetate and washed with 5% HCl (2 10 mL), 5% NaHCO3(2 10 mL), saturated NaCl solution (2 10 mL), and dried over anhydrousNa2SO4 and the evaporation of the solvent gave a residue that was purified onsilica gel column chromatography using hexane and ethyl acetate.
61%	With hydroxylamine potassium salt In methanol for 2h;

10%	With 4-methyl-morpholine; 1,3,5-trichloro-2,4,6-triazine; hydroxylamine hydrochloride In dichloromethane at 20℃; for 14h;
	Multi-step reaction with 2 steps 1: 3,3-dichloro-1,2-diphenylcyclopropene; N-ethyl-N,N-diisopropylamine / dichloromethane / 0.17 h / -10 - 20 °C 2: hydroxylamine hydrochloride; potassium hydroxide / methanol; dichloromethane / 0.75 h / -10 °C

Reference： [1]Giacomelli, Giampaolo; Porcheddu, Andrea; Salaris, Margherita [Organic Letters, 2003, vol. 5, # 15, p. 2715 - 2717]
[2]Manne, Srinivasa Rao; Thalluri, Kishore; Giri, Rajat Subhra; Paul, Ashim; Mandal, Bhubaneswar [Tetrahedron Letters, 2015, vol. 56, # 44, p. 6108 - 6111]
[3]Zhang, Lei; Wang, Xuejian; Li, Xiaoguang; Xu, Wenfang [Journal of Enzyme Inhibition and Medicinal Chemistry, 2014, vol. 29, # 3, p. 333 - 337]
[4]Ahlford, Katrin; Zaitsev, Alexey B.; Ekström, Jesper; Adolfsson, Hans [Synlett, 2007, # 16, p. 2541 - 2544]
[5]Vathsala; Srinivasulu; Santhosh; Sureshbabu, Vommina V. [Arkivoc, 2018, vol. 2018, # 7, p. 449 - 457]

10
[ 2900-27-8 ]
[ 63038-27-7 ]
(S)-2-((S)-2-tert-Butoxycarbonylamino-2-phenyl-acetylamino)-3,3-dimethyl-butyric acid methyl ester [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2004,vol. 14,p. 5007 - 5011

11
[ 7737-17-9 ]
[ 2900-27-8 ]
[ 786652-77-5 ]

Reference： [1]Synlett,2004,p. 2031 - 2033

12
[ 6946-05-0 ]
[ 2900-27-8 ]
[ 786652-78-6 ]

Reference： [1]Synlett,2004,p. 2031 - 2033

13
[ 2900-27-8 ]
[ 1117-97-1 ]
[ 216769-51-6 ]

Yield	Reaction Conditions	Operation in experiment
95%	Stage #1: (2S)-2-[(tert-butoxycarbonyl)amino]-2-phenylethanoic acid; N,0-dimethylhydroxylamine In toluene at 0℃; for 0.166667h; Stage #2: With phosphorus trichloride In toluene at 20 - 60℃; for 0.5h;	N-Methoxy-N-methylbenzamide (3a);^38,39Typical Procedure General procedure: A solution of NHMe(OMe) (0.360 g, 6.0 mmol) and benzoic acid (0.244 g, 2.0 mmol) was stirred in dry toluene (10 mL) at 0 °C for 10 min. A solution of PCl3 (0.137 g, 1.0 mmol) in dry toluene (2 mL) was then added dropwise to the mixture. The mixture was warmed to r.t. slowly and then stirred at 60 °C for 0.5 h. When the reaction was complete (TLC monitoring), the mixture was cooled to r.t. The mixture was then quenched with sat. NaHCO3 soln (20 mL) and extracted with EtOAc (3 × 10 mL). The combined organic layers were dried (anhyd MgSO4). The solvent was removed in vacuo.The product was purified by column chromatography (silica gel, petroleum ether-EtOAc, 3:2) to give pure 3a as a colorless oil; yield: 320 mg (97%).
90%	With 4-methyl-morpholine; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 0 - 20℃;
	With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine In dichloromethane at 20℃; for 3h;	54I.3 Step 3 : Synthesis of (^-tert-butyl (2-(methoxymethyl)amino)-2-oxo-l-phenylethyl)carbamate To the solution of (,S)-2-((tert-butoxycarbonyl)amino)-2-phenylacetic acid (0.5 g, 1.93 mmol) in dichloromethane (6 mL) was added Ν,Ο-dimethylhydroxylamine (0.233 g, 2.38 mmol). To the resulting mixture was then added HOBT (0.082 g, 0.53 mmol), EDCI.HC1 (0.457 g, 2.38 mmol) and DIPEA (0.87 mL, 4.96 mmol). The reaction mixture was stirred at ambient temperature for 3 h. TLC analysis indicated complete consumption of the starting material. The reaction mixture was bi-phased with dichloromethane (25 mL) and water (15 mL). The aqueous layer was extracted with dichloromethane (2 x 10 mL). The combined organic layers were washed with brine (1 x 10 mL), dried (Na2S04) and concentrated under reduced pressure to afford the title compound. MS calc'd for C15H22N2O4 [M+H]+ 295; Found: 195.2 (M+l-Boc); 1H MR (400 MHz, CDC13) δ 7.41-7.24 (m, 5H), 5.80 (d, 1H, J= 7.6 Hz), 5.72 (d, 1H, J= 7.5 Hz), 3.47 (s, 3H), 3.19 (s, 3H), 1.43 (s, 9H)

Reference： [1]Niu, Teng; Wang, Ke-Hu; Huang, Danfeng; Xu, Changming; Su, Yingpeng; Hu, Yulai; Fu, Ying [Synthesis, 2014, vol. 46, # 3, p. 320 - 330]
[2]Lescop, Cyrille; Herzner, Holger; Siendt, Herve; Bolliger, Reto; Henneboehle, Marco; Weyermann, Philipp; Briguet, Alexandre; Courdier-Fruh, Isabelle; Erb, Michael; Foster, Mark; Meier, Thomas; Magyar, Josef P.; Von Sprecher, Andreas [Bioorganic and Medicinal Chemistry Letters, 2005, vol. 15, # 23, p. 5176 - 5181]
[3]Current Patent Assignee: PHARMARON INC - WO2016/100050, 2016, A1 Location in patent: Page/Page column 82-84

14
[ 2900-27-8 ]
[ 117049-14-6 ]

Yield	Reaction Conditions	Operation in experiment
95.3%	With borane-THF In tetrahydrofuran at 0 - 20℃; for 2h; Inert atmosphere;	1-3 Example 3 Under the protection of nitrogen, 50g (0.199mol) of N-Boc-L-phenylglycine and 100mL of tetrahydrofuran were mixed, and the temperature was lowered to 0C and control the temperature to add (BH3-THF, 1.0M) 600mL dropwise at 0-20C, the dropwise addition is complete, continue to stir for 2 hours, until TLC detectionThe raw material reaction is complete.Cool the reaction solution to about -10C, slowly add methanol dropwise to quench the reaction, and wait until no bubbles overflowWhen the temperature is raised to room temperature, continue to stir for 1 hour, then distill under reduced pressure to generate trimethyl borate and tetrahydrofuran solvent, and distill to noLiquid, add heptane/MTBE (6/1, 185mL) to beat to obtain 45.0g of N-Boc-L-phenylglycinol, HPLC: 97.6%, yield95.3%.
65%	Stage #1: (2S)-2-[(tert-butoxycarbonyl)amino]-2-phenylethanoic acid With triethylamine In tetrahydrofuran Stage #2: With sodium tetrahydroborate In water
61%	With borane-THF In tetrahydrofuran at 20℃; for 3.5h;

	Stage #1: (2S)-2-[(tert-butoxycarbonyl)amino]-2-phenylethanoic acid With 4-methyl-morpholine; isobutyl chloroformate In tetrahydrofuran at -10℃; Stage #2: With sodium tetrahydroborate In tetrahydrofuran
	Stage #1: (2S)-2-[(tert-butoxycarbonyl)amino]-2-phenylethanoic acid With isobutyl chloroformate In 1-methyl-pyrrolidin-2-one at -10℃; Stage #2: With sodium tetrahydroborate In N,N-dimethyl-formamide at -10℃;
	Multi-step reaction with 2 steps 1: 85 percent / K₂CO₃ / dimethylformamide / 1 h / 0 - 20 °C 2: 89 percent / LiAlH₄ / tetrahydrofuran / 1 h / 0 - 20 °C
	Multi-step reaction with 2 steps 1: NEt₃ / tetrahydrofuran / -10 °C 2: NaBH₄ / H₂O / 0 °C
	Stage #1: (2S)-2-[(tert-butoxycarbonyl)amino]-2-phenylethanoic acid With 4-methyl-morpholine; chloroformic acid ethyl ester In tetrahydrofuran at -15℃; for 0.25h; Stage #2: With sodium tetrahydroborate In tetrahydrofuran for 0.5h; Stage #3: With water In tetrahydrofuran for 0.25h;

Reference： [1]Current Patent Assignee: GANSU HANJU PHARMACEUTICAL - CN112500361, 2021, A Location in patent: Paragraph 0022-0024; 0026-0028; 0030-0032
[2]Fotaras, Stamatis; Kokotos, Christoforos G.; Kokotos, George [Organic and Biomolecular Chemistry, 2012, vol. 10, # 29, p. 5613 - 5619]
[3]Yan, Shunqi; Appleby, Todd; Larson, Gary; Wu, Jim Z.; Hamatake, Robert K.; Hong, Zhi; Yao, Nanhua [Bioorganic and Medicinal Chemistry Letters, 2007, vol. 17, # 7, p. 1991 - 1995]
[4]Alper, Phillip B.; Liu, Hong; Chatterjee, Arnab K.; Nguyen, Khanhlinh T.; Tully, David C.; Tumanut, Christine; Li, Jun; Harris, Jennifer L.; Tuntland, Tove; Chang, Jonathan; Gordon, Perry; Hollenbeck, Thomas; Karanewsky, Donald S. [Bioorganic and Medicinal Chemistry Letters, 2006, vol. 16, # 6, p. 1486 - 1490]
[5]Thomas, Sheela A.; Li, Tongmei; Woods, Keith W.; Song, Xiaohong; Packard, Garrick; Fischer, John P.; Diebold, Robert B.; Liu, Xuesong; Shi, Yan; Klinghofer, Vered; Johnson, Eric F.; Bouska, Jennifer J.; Olson, Amanda; Guan, Ran; Magnone, Shayna R.; Marsh, Kennan; Luo, Yan; Rosenberg, Saul H.; Giranda, Vincent L.; Li, Qun [Bioorganic and Medicinal Chemistry Letters, 2006, vol. 16, # 14, p. 3740 - 3744]
[6]Bodas, Mandar S.; Upadhyay, Puspesh K.; Kumar, Pradeep [Tetrahedron Letters, 2004, vol. 45, # 5, p. 987 - 988]
[7]Catalano, John G; Deaton, David N; Furfine, Eric S; Hassell, Annie M; McFadyen, Robert B; Miller, Aaron B; Miller, Larry R; Shewchuk, Lisa M; Willard Jr., Derril H; Wright, Lois L [Bioorganic and medicinal chemistry letters, 2004, vol. 14, # 1, p. 275 - 278]
[8]Santhosh; Durgamma; Shekharappa; Sureshbabu, Vommina V. [Organic and Biomolecular Chemistry, 2018, vol. 16, # 26, p. 4874 - 4880]

15
[ 67-56-1 ]
[ 2900-27-8 ]
[ 143978-88-5 ]

Yield	Reaction Conditions	Operation in experiment
97%	With 4-methyl-morpholine; 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride
40%	Stage #1: (2S)-2-[(tert-butoxycarbonyl)amino]-2-phenylethanoic acid With 1,1'-carbonyldiimidazole In N,N-dimethyl-formamide at 60℃; for 0.833333h; Inert atmosphere; Stage #2: methanol In N,N-dimethyl-formamide for 12h;	143.1 To a solution of 1, 1'-carbonyldiimidazole (CDI) (770 mg, 4.8 mmol) in anhydrous DMF (10 mL) was added (S) -2- ( (tert-butoxycarbonyl) amino) -2-phenylacetic acid (1.0 g, 4.0 mmol) at rt.The mixture was stirred at 60 for 50 min, and methanol (10 mL) was added. The resulting mixture was futher stirred for 12 h, and concentrated. The residue was diluted with water (10 mL) , and extracted with EtOAc (10 mL × 3) . The combined organic layers were dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel chromatography eluted with Petroleum ether/EtOAc (v/v) 8/1 to give (S) -methyl 2- ( (tert-butoxycarbonyl) amino) -2-phenylacetate as a a light yellow solid (426 mg, 40) .1H NMR (400 MHz, CDCl3) : δ ppm 7.31-7.36 (m, 5H) , 5.22 (s, 1H) , 5.32 (d, J 7.1 Hz, 1H) , 3.72 (s, 3H) , 1.43 (s, 9H) and MS-ESI: m/z 288.00 [M+Na] +.
134 mg	In benzene at 20℃; for 2h; Molecular sieve;

Reference： [1]Current Patent Assignee: TOKUYAMA CORPORATION - EP1178043, 2002, A1 Location in patent: Page 31, 32
[2]Current Patent Assignee: SHENZHEN DONGYANGGUANG INDUSTRIAL DEVELOPMENT CO LTD - WO2016/34134, 2016, A1 Location in patent: Paragraph 00729
[3]Wei, Yu; He, Wei; Liu, Yulong; Liu, Peng; Zhang, Shengyong [Organic Letters, 2012, vol. 14, # 3, p. 704 - 707]

16
(6,7-cis)-6-amino-7-(1-napthyl)-1,4-thiazepan-5-one hydrobromide [ No CAS ]
[ 2900-27-8 ]
[ 680230-73-3 ]

Yield	Reaction Conditions	Operation in experiment
95%	With 4-methyl-morpholine; benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 0 - 20℃; for 2h;	26.a a. tert-Butyl ((1S)-2-[(6,7-cis)-7-(1-naphthyl)-5-oxo-1,4-thiazepan-6-yl]amino}-2-oxo-1- phenylethyl) carbamate (26a) To a solution of (6, 7-cis)-6-amino-7-(1-naphthyl)-1, 4-thiazepan-5-one 25e (162 mg, 0.545 mmol) in dichloromethane [(15ML)] at [0°C] under nitrogen was added [(22-[(TERT-] butoxycarbonyl) amino] (phenyl) acetic acid (137 mg, 0.545 mmol) followed by HOBt-hydrate [(190MG,] 1.24mmol), EDAC. HCI (162mg, 0.850mmol) and NMM (93 [1L,] 0. [850MMOL).] The reaction mixture was stirred 1.5 h at [0°C] and for 30 min at RT, concentrated in vacuo and partitioned between [H20] (25ml) and ethyl acetate (25ml). The organic phase was collected and consecutively washed with 0.5 N HCl (2x), H20, brine, dried and the solvent removed in vacuo to give the title compound 29a (272 mg, 95%) as a light pink solid. MS APCI, [M/Z =] 528 (M+Na), [LC/MS] : 2.36 min.

Reference： [1]Current Patent Assignee: ASTRAZENECA PLC - WO2004/31154, 2004, A1 Location in patent: Page 68

17
(6,7-cis)-6-amino-4-methyl-7-phenyl-1,4-oxazepan-5-one hydrochloride [ No CAS ]
[ 2900-27-8 ]
[ 680230-94-8 ]

Yield	Reaction Conditions	Operation in experiment
72%	With 4-methyl-morpholine; benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 0℃; for 2h;	34.a tert-Butyl ((1S)-2-[(6,7-cis)-4-methyl-5-oxo-7-phenyl-1,4-oxazepan-6-yl]amino}-2-oxo- 1-phenylethyl)carbamate (34a To a suspension of (6, [7-CIS)-6-AMINO-4-METHYL-7-PHENYL-1,] 4-oxazepan-5-one hydrochloride [(30D)] (300mg, 1.17 mmol) in dichloromethane (30ml) at [0°C] under N2 was added [(2S)- [ (TERT-BUTOXYCARBONYL)] amino] (phenyl) acetic acid (293 mg, 1.17 mmol) followed [BY NMM (128, UL,] 1. [17MMOL)] and the mixture stirred 5 min. until solution cleared. To the reaction was added HOBt-hydrate (389mg, 2. [60MMOL),] EDAC. [HC1] (336mg, 1. [76MMOL)] and NMM (193 µL, 1.76 mmol). The reaction mixture was stirred 2 h at [0°C,] concentrated in vacuo and partitioned between water and ethyl acetate. The organic phase was collected and consecutively washed with 0.25 N [HC1] (2x), water, brine, dried and the solvent removed in vacuo to give the title compound [34A] (380 mg, 72%) as a off white solid. MS APCI, [M/Z =] 454 [(M+1)] 476 (M+Na), LC/MS: 2.15 min.

Reference： [1]Current Patent Assignee: ASTRAZENECA PLC - WO2004/31154, 2004, A1 Location in patent: Page 76

18
(6,7-cis)-6-amino-7-phenyl-1,4-thiazepan-5-one hydrobromide [ No CAS ]
[ 2900-27-8 ]
[ 680231-23-6 ]

Yield	Reaction Conditions	Operation in experiment
97%	With 4-methyl-morpholine; benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In DMF (N,N-dimethyl-formamide) at 20℃;	50.a a. [TERT-BUTYL ( (LS)-2-OXO-2-1 [ (6, 7-CIS)-5-OXO-7-PHENVL-1, 4-THIAZEPAN-6-VLLAMINOL-L-] phenylethyl) carbamate (50a) To a stirred solution of (6, 7-cis)-6-amino-7-phenyl-1, 4-thiazepan-5-one hydrobromide 48a) (150 mg, 0.497 mmol) in DMF (2 mL) under nitrogen was added, (2S)-[(tert- butoxycarbonyl) amino] (phenyl) acetic acid (137 mg, 0.544 mmol), HOBt (100 mg, 0.742 mmol), NMM (75 mg, 0.742 mmol) and EDAC-HC1 (142 mg, 0.742 mmol). The mixture was stirred at ambient temperature overnight. The reaction mixture was diluted with saturated aqueous sodium bicarbonate and extracted with ethyl acetate. The organic solution was separated, extracted in succession with IN aqueous HCl and brine then dried, filtered and evaporated to afford the title compound (221 mg, 97%) as a white solid. [IH] NMR (300 MHz, [CDC13)] [81.] 40 (br s, 9H), 2.74 (m, 1H), 2.98-3. 20 (m, 1H), 3.56-3. 95 (m, 2H), 4.03 (br d, 0.5H), 4. [37] (d, 0.5H, J= 3.9 Hz), 5.12-5. 44 (m, 2H), 5.61 (br d, 0.5H), 5.84 (br d, 0.5H), 6.21 (br 0.5H), 6.58 (br, 0.5H), 6.79 (br d, 1H), 6.96-7. 19 (m, 2H), 7.22-7. 38 (m, 8H). MS APCI, [M/Z=] 456 [(M+1).] LC/MS: 2.63 min.

Reference： [1]Current Patent Assignee: ASTRAZENECA PLC - WO2004/31154, 2004, A1 Location in patent: Page 92

19
(2,3-cis)-3-amino-2-phenyl-2,3-dihydro-1,5-benzoxazepin-4(5H)-one hydrochloride [ No CAS ]
[ 2900-27-8 ]
[ 680231-36-1 ]

Yield	Reaction Conditions	Operation in experiment
89%	With 4-methyl-morpholine; benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 20℃;	58.a a. tert-Butyl ((1S)-2-oxo-2-[ (2, [3-CIS)-4-OXO-2-PHENYL-2,] 3,4,5-tetrahydro-1, 5- [BENZOXAZEPIN-3-YLLAMINOL-1-PHENYLETHYL)] carbamate [(58A)] To a stirred solution of (2, 3-cis)-3-amino-2-phenyl-2, [3-DIHYDRO-1,] 5-benzoxazepin- 4 (5H)-one [(] [(98] mg, 0.337 mmol) in dichloromethane (3 mL) was added [(22-[(TERT-] butoxycarbonyl) amino] (phenyl) acetic acid (93 mg, [0.] 370 mmol), HOBt (55 mg, 0.407 mmol), NMM (68 mg, 0.673 mmol) and EDAC-HCl (78 mg, 0.407 mmol). The mixture was stirred at ambient temperature under nitrogen overnight. The reaction mixture was diluted with water and extracted with ethyl acetate three times. The combined organic extracts were washed in succession with saturated aqueous sodium bicarbonate and IN [AQUEOUS HCI.] The organic solution was dried, filtered and evaporated. The residue was purified by flash chromatography on silica gel eluting with 2: 1 [(V/V)] hexane: ethyl acetate to afford the title compound (146 mg, 89%) as a yellow [SOLID. 1H] NMR (300 MHz, CDCl3) [81.] 34 (s, 4.5H), 1.44 (s, 4.5H), 5.17 (m, 1H), 5.55 (m, 1H), 5.73 (d, 0.5H, J= 7.5 Hz), 5.85 (d, 0.5H, J= 7.0 Hz), 6.44-6. 73 (br, 1H), 6.91-7. 12 (m, 3H), 7.14-7. 41 (m, 12H), 7.63 (br s, 0.5H), 8.15 (br, 0.5H). MS APCI, m/z [= 510] (M+Na). [LC/MS] : 2.60 min.

Reference： [1]Current Patent Assignee: ASTRAZENECA PLC - WO2004/31154, 2004, A1 Location in patent: Page 101

20
[ 5266-85-3 ]
[ 2900-27-8 ]
[ 672960-86-0 ]

Yield	Reaction Conditions	Operation in experiment
57%	With 4-methyl-morpholine; isobutyl chloroformate;	tert-butyl [[1- (2-ISOPROPYL-6-METHYLPHENYLCARBAMOYL)-1-PHENYL-METHYL]-] carbamate was isolated as a white solid (216. 1mg, 57%) from BOC- phenylglycine (250. Omg, 0. [99MMOL),] [N-METHYLMORPHOLINE] (0.12mL, 1. 09mmol), isobutylchloroformate (0.14mL, 1. [09MMOL), 2-ISOPROPYL-6-] [METHYLANILINE (0. 19ML,] 1. [19MMOL)] and [N-METHYLMORPHOLINE] (0.13mL, 1. [19MMOL).

Reference： [1]Patent: WO2004/22534,2004,A1 .Location in patent: Page 92

21
[ 2246-44-8 ]
[ 2900-27-8 ]
[ 672960-98-4 ]

Yield	Reaction Conditions	Operation in experiment
43%	With 4-methyl-morpholine; isobutyl chloroformate;	TERT-BUTYL [1- (2-METHYL-1-NAPHTHYLCARBAMOYL)-1-PHENYL-METHYL]-CARBAMATE WAS] isolated as an off-white solid (165.7mg, 43%) from BOC-phenyl glycine (250. Omg, 0. 99mmol), N-methylmorpholine (0.12mL, 1. 09mmol), [ISOBUTYLCHLOROFORMATE] (0.14mL, 1. [09MMOL), 2-METHYL-1-NAPHTHYLAMINE] [(187.] 7mg, 1. 19mmol) and N-methylmorpholine (0. [13ML,] 1. 19mmol).

Reference： [1]Patent: WO2004/22534,2004,A1 .Location in patent: Page 98

22
[ 2900-27-8 ]
[ 100-46-9 ]
[ 117422-78-3 ]

Yield	Reaction Conditions	Operation in experiment
87%	With O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate; N-ethyl-N,N-diisopropylamine In dichloromethane at -20℃; for 24h;
80%	With tris(2,2,2-trifluoroethyl) borate at 100℃; for 24h;
71%	Stage #1: (2S)-2-[(tert-butoxycarbonyl)amino]-2-phenylethanoic acid With O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate; triethylamine In dichloromethane for 0.333333h; Stage #2: benzylamine In dichloromethane at 20℃; for 8h;

62%	With N-ethyl-N,N-diisopropylamine In 4-(dicyanomethylene)-2-methyl-6-(p-dimethylaminostyryl)-4H-pyran	1.e (S)-1-Ethyl-5-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-1H-indole-2-carboxylic acid {2-[benzyl(methyl)amino]-2-oxo-1-phenylethyl} amide: (e) (S)-(Benzylcarbamoyl-phenyl-methyl)-carbamic Acid Tert-Butyl Ester. (S)-tert-Butoxycarbonylamino-phenyl-acetic acid (1.00 g, 4 mmol) was dissolved in DCM (15 mL). Benzylamine (0.428 g, 4 mmol) and DIEA(0.65 g, 5 mmol) were added to the above mixture. The mixture which resulted was stirred at room temperature for a few minutes. PyBroP(2.10 g, 4.5 mmol) was added to the above solution in one portion and the reaction mixture was stirred overnight. The reaction mixture was diluted with DCM (150 mL) and washed with NaHCO3 (50 mL*2, sat.). The organic layer was collected and dried (Na2SO4) and the solvent was removed under reduced pressure. The crude product was purified by chromatography to provide the desired product (0.85 g, 62%).
62%	Stage #1: (2S)-2-[(tert-butoxycarbonyl)amino]-2-phenylethanoic acid; benzylamine With N-ethyl-N,N-diisopropylamine In dichloromethane at 20℃; Stage #2: With bromo-tris(1-pyrrolidinyl)phosphonium hexafluorophosphate In dichloromethane	1 Preparation of Intermediate (S) (Benzylcarbamoyl-phenyl-methyl)-carbamic acid tert-butyl ester (I-1c) The (S)-tert-Butoxycarbonylamino-phenyl-acetic acid I-2b (1.00 g, 4 mmol) was dissolved in dichloromethane (DCM) (15 ml).benzylamine (0.428 g, 4 mmol) and diisopropylethylamine (DIEA) (0.65 g, 5 mmol) were added to the above mixture.The mixture was stirred at room temperature for a few minutes. bromo-trispyrrolidino-phosphonium hexafluorophosphate (PyBroP) (2.10 g, 4.5 mmol) was added to the above solution in one portion and the reaction mixture was stirred overnight.The reaction mixture was diluted with dichloromethane (150 ml) and washed with NaHCO3 (50 ML*2, sat.).The organic layer was collected and dried (Na2SO4).The solvent was removed under reduced pressure.The crude product was purified by chromatography to provide the desired product (0.85 g, 62%).
	With N-ethyl-N,N-diisopropylamine; bromo-tris(1-pyrrolidinyl)phosphonium hexafluorophosphate In dichloromethane at 0 - 20℃;
	With O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; N-ethyl-N,N-diisopropylamine In dichloromethane at 20℃; Inert atmosphere;
	With 1-hydroxy-7-aza-benzotriazole; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In N,N-dimethyl-formamide at 5 - 20℃; for 2h;	Step 2: tert-butyl (S)-(2-(benzylamino)-2-oxo-1-phenylethyl)carbamate (116a). A solution of EDCI (1.1 eq) and HOAt (1.3 eq) in dry DMF (5 mL) was stirred at 5 °C for 10 min, then (S)-2-((tert-butoxycarbonyl)amino)-2-phenylacetic acid 115a (0.50 g, 1.99 mmol) was added and stirring was continued for 10 min before the addition of benzylamine (0.23 mL, 2.09 mmol). After complete addition, the cooling bath was removed and stirring was continued at rt for 2 h. After completion, the mixture was diluted with water and the precipitated solid was filtered off, washed with water, and dried. The crude product (566 mg, 83%, off-white solid) was used in the next step without further purification. LCMS (ES+) m/z calculated for C20H24N2O3 340.18, found 241 (M+H-Boc)+.
	With 1-hydroxy-7-aza-benzotriazole; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In N,N-dimethyl-formamide at 5 - 20℃; for 2h;	Step 2: tert-butyl (S)-(2-(benzylamino)-2-oxo-1-phenylethyl)carbamate (116a). A solution of EDCI (1.1 eq) and HOAt (1.3 eq) in dry DMF (5 mL) was stirred at 5 °C for 10 min, then (S)-2-((tert-butoxycarbonyl)amino)-2-phenylacetic acid 115a (0.50 g, 1.99 mmol) was added and stirring was continued for 10 min before the addition of benzylamine (0.23 mL, 2.09 mmol). After complete addition, the cooling bath was removed and stirring was continued at rt for 2 h. After completion, the mixture was diluted with water and the precipitated solid was filtered off, washed with water, and dried. The crude product (566 mg, 83%, off-white solid) was used in the next step without further purification. LCMS (ES+) m/z calculated for C20H24N2O3 340.18, found 241 (M+H-Boc)+.

Reference： [1]Zhang, Jian; Yu, Peiyuan; Li, Shao-Yu; Sun, He; Xiang, Shao-Hua; Wang, Jun; Houk, Kendall N.; Tan, Bin [Science, 2018, vol. 361, # 6407]
[2]Karaluka, Valerija; Lanigan, Rachel M.; Murray, Paul M.; Badland, Matthew; Sheppard, Tom D. [Organic and Biomolecular Chemistry, 2015, vol. 13, # 44, p. 10888 - 10894]
[3]Zhang, Lei; Wang, Xuejian; Li, Xiaoguang; Zhang, Lihui; Xu, Wenfang [Journal of Enzyme Inhibition and Medicinal Chemistry, 2014, vol. 29, # 4, p. 582 - 589]
[4]Current Patent Assignee: ZOETIS INC. - US2003/187053, 2003, A1
[5]Current Patent Assignee: PFIZER INC - US2004/132745, 2004, A1 Location in patent: Page/Page column 19
[6]Li, Jin; Bertinato, Peter; Cheng, Hengmiao; Cole, Bridget M.; Bronk, Brian S.; Jaynes, Burton H.; Hickman, Anne; Haven, Michelle L.; Kolosko, Nicole L.; Barry, Chris J.; Manion, Tara B. [Bioorganic and Medicinal Chemistry Letters, 2006, vol. 16, # 11, p. 3039 - 3042]
[7]Zhou, Zhipeng; Zheng, Xiaojun; Liu, Jialin; Li, Jinlei; Wen, Pushan; Wang, Haifei [Synlett, 2017, vol. 28, # 8, p. 999 - 1003]
[8]Abate, Luigi; Amaudrut, Jerome; Beghetto, Elisa; Bianchi, Elisabetta; Bresciani, Alberto; Colarusso, Stefania; Conte, Immacolata; Ferrigno, Federica; Missineo, Antonino; Montalbetti, Christian; Ontoria, Jesus M.; Paonessa, Giacomo; Pavone, Francesca; Ponzi, Simona; Tomei, Licia; Toniatti, Carlo [Bioorganic and Medicinal Chemistry, 2022, vol. 57]
[9]Abate, Luigi; Amaudrut, Jerome; Beghetto, Elisa; Bianchi, Elisabetta; Bresciani, Alberto; Colarusso, Stefania; Conte, Immacolata; Ferrigno, Federica; Missineo, Antonino; Montalbetti, Christian; Ontoria, Jesus M.; Paonessa, Giacomo; Pavone, Francesca; Ponzi, Simona; Tomei, Licia; Toniatti, Carlo [Bioorganic and Medicinal Chemistry, 2022, vol. 57]

23
[ 2900-27-8 ]
[ 94838-59-2 ]
[ 849540-58-5 ]

Yield	Reaction Conditions	Operation in experiment
	With 1-hydroxy-7-aza-benzotriazole; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; In DMF (N,N-dimethyl-formamide); at 0 - 20℃; for 1.66667h;	Example 9: Synthesis OF N [5- ( (R)-2- {2- [4- ( (-2-AMINO-2-PHENYL- ethylamino) phenyl] ETHYLAMINO}-L-HYDROXYETHYL)-2-HYDROXYPHENYL]- formamide; a. Preparation of (- { [4- (2-TERT-BUTOXYCARBONYLAMINOETHYL) PHENYLCARBAMOYL] PHENYL- methylcarbamic acid tert-butyl ester; [2- (4-AMINOPHENYL) ethyl] carbamic acid tert-butyl ester (3.95 g, 16.7 mmol) and ( (S)-TERT-BUTOXYCARBONYLAMINO) phenylacetic acid (3.97 g, 15.7 mmol) were dissolved with a 0.5 M solution OF 1-HYDROXY-7-AZABENZOTRIAZOLE IN N, N DIMETHYLFORMAMIDE (31.76 ML) under nitrogen and cooled to 0C. 1- (3-DIMETHYLAMINOPROPYL)-3-ETHYLCARBODIIMIDE hydrochloride (3.57 g, 18.6 mmol) was added and the mixture stirred at 0 C FOR 10 minutes, then at room temperature for 1.5 hours. The mixture was partitioned between water and ethyl acetate, and the organics washed with 1.0 N HC1, saturated sodium hydrogencarbonate, and saturated sodium chloride. The organics were then dried over sodium sulfate and evaporated to dryness. The title intermediate was used without further purification.

Reference： [1]Patent: WO2005/30678,2005,A2 .Location in patent: Page/Page column 53

24
[ 405-66-3 ]
[ 2900-27-8 ]
[ 863492-49-3 ]

Yield	Reaction Conditions	Operation in experiment
96%	With N-ethyl-N,N-diisopropylamine; bromo-tris(1-pyrrolidinyl)phosphonium hexafluorophosphate In dichloromethane at 0 - 20℃;	114.c c) Preparation intermediate of (S)- [(4- Fluorobenzyl)methylcarbamoyl]phenylmethyl}carbamic acid tert-butyl ester; A solution of N-Boc-L-phenylglycine (H, 17.2 g, 68.5 mmol) and (4- fluorobenzyl) methylamine (10.47 g, 75.3 mmol) in CH2C12 (550 mL) was cooled to 0°C. Disopropylethylamine (35.8 mL, 205 mmol) and PyBrOP (38.3 g, 82.1 mmol) were then added sequentially. The cooling bath was removed and the reaction mixture was stirred at room temperature overnight. The solvent was evaporated and the title compound (24.5 g, 96%) was isolated by chromatography on silica gel eluting with a gradient of 40% to 60% ethyl acetate in hexane.
81%	With benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate; N-ethyl-N,N-diisopropylamine In dichloromethane at 0 - 20℃; for 18h;	A mixture containing (5)-2-(ter/-butoxycarbonylamino)-2-phenylacetic acid (4.0 g, 15.9 mmol) and l -(4-fluorophenyl)-N-methylmethanamine (2.4 mL, 17.5 mmol) in CH2Cl2 (50 mL) was cooled in an ice bath under an inert atmosphere of argon. Diisopropylethylamine (DIPEA, 7.9 mL, 47.7 mmol) and PyBOP (8.9 g, 19.1 mmol) were added sequentially. The resulting reaction mixture was wanned to room temperature and stirred for 18 h. It was then concentrated under reduced pressure and the resulting residue was purified by chromatography (gradient elution: EtOAc/petroleum ether=12: l ~8: 1 ) to afford (S)-tert-buty 2-((4-fluorobenzyl)(methyl)amino)-2-oxo-l -phenyl ethylcarbamate as a yellow syrup (4.83 g, yield: 81 %). 1HNMR (400MHz, CDCl3) δ: 7.41-7.32 (5H, m), 7.14 (2H, m), 6.99 (2H, m), 6.05 (IH, d, J= 8. 0 Hz), 5.60 (IH, d, J= 7.6 Hz), 4.61 (2H, m), 2.86 (IH, s), 2.81 (2H, s).
81%	With benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate; N-ethyl-N,N-diisopropylamine In dichloromethane at 0 - 20℃; for 18h;	1 Preparation of (S)-tert-butyl 2-((4-fluorobenzyl)(methyl)amino)-2-oxo-l- phenylethyl carbamate:A mixture containing (S)-2-(7ert-butoxycarbonylamino)-2-phenylacetic acid (4.0 g, 15.9 mmol) and l -(4-fluorophenyl)-N-methylmethanamine (2.4 mL, 17.5 mmol) in CH2Cl2 (50 mL) was cooled in an ice bath under an inert atmosphere of argon. Diisopropylethylamine (DIPEA, 7.9 mL, 47.7 mmol) and PyBOP (8.9 g, 19.1 mmol) were then added sequentially. The resulting reaction mixture was warmed to room temperature and stirred for 18 h. It was then concentrated under reduced pressure and the resulting residue was purified by chromatography (gradient elution: EtO Ac/petroleum ether=12:l ~8:l) to afford (S)-tert-buty 2-((4- fluorobenzyl)(methyl)amino)-2-oxo-l -phenylethyl carbamate as a yellow syrup (4.83 g, yield: 81%). 1HNMR (400MHz, CDCl3) δ: 7.41-7.32 (5H, m), 7.14 (2H, m), 6.99 (2H, m), 6.05 (IH, d, J= 8. 0 Hz), 5.60 (IH, d, J= 7.6 Hz), 4.61 (2H, m), 2.86 (IH, s), 2.81 (2H, s).

Reference： [1]Current Patent Assignee: PFIZER INC - WO2005/80373, 2005, A1 Location in patent: Page/Page column 111-112
[2]Current Patent Assignee: GLAXOSMITHKLINE PLC - WO2008/100423, 2008, A1 Location in patent: Page/Page column 87-88
[3]Current Patent Assignee: GLAXOSMITHKLINE PLC - WO2009/14674, 2009, A1 Location in patent: Page/Page column 81

25
[ 2900-27-8 ]
[ 13143-47-0 ]
[ 890524-41-1 ]

Yield	Reaction Conditions	Operation in experiment
	With 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; In N,N-dimethyl-formamide; at 20℃; for 1h;	B. Preparation of (2S) N-[4-(2-rhoyridon-l-yl)rhohenyl]-2-phenyl-2-(4- chlorophenylaminocarbonylamino)-acetamide; [0497] To a solution of (L) N-BOC-phenylglycine (126 mg, 0.500 mmol) and 4-(2- rhoyridon-l-yl)phenylamine (102 mg, 0.548 mmol) in DMF (3 mL), EDC (144 mg, 0.750 mmol) was added. The mixture was stirred at room temperature for 1 h. Water (10 mL) was added to induce precipitation. The precipitate was collected by filtration to give the amide (61 mg). MS 420.2 (M+H).[0498] The amide (61 mg, 0.15 mmol) was dissolved in TFA (4 mL). After being stirred at room temperature for 1 h, TFA was removed in vacuo. The residue was partitioned between EPO <DP n="120"/>EtOAc and aq. 5% NaHCO3. The EtOAc phase was separated, dried over Na2SO4, concentrated in vacuo to give a solid (35 mg).[0499] To a solution of the solid (17 mg, 0.053 mmol) in CH3CN (2 mL), 4- chlorophenylisocyanate (20 mg, 0.13 mmol) was added. After being stirred at room temperature for 30 min, the mixture was purified by HPLC to give the titled compound (10 mg). MS 473.2 and 475.2 (M+H, Cl pattern)
	With 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; In N,N-dimethyl-formamide; at 20℃; for 1h;	B. Preparation of (2S) N-[4-(2-pyridon-l-yl)phenyl]-2-phenyl-2-(4- chlorophenylaminothiocarbonylamino)-acetamide; [0187] To a solution of (L) N-BOC-phenylglycine (126 mg, 0.500 mmol) and 4-(2- rhoyridon-l-yl)phenylamine (102 mg, 0.548 mmol) in DMF (3 mL), EDC (144 mg, 0.750 mmol) was added. The mixture was stirred at room temperature for 1 h. Water (10 mL) was added to induce precipitation. The precipitate was collected by filtration to give the amide (61 mg). MS 420.2 (M+H).[0188] The amide (61 mg, 0.15 mmol) was dissolved in TFA (4 mL). After being stirred at room temperature for 1 h, TFA was removed in vacuo. The residue was partitioned between EtOAc and aq. 5% NaHCO3. The EtOAc phase was separated, dried over Na2SO4, concentrated in vacuo to give a solid (35 mg).[0189] To a solution of the solid (17 mg, 0.053 mmol) in CH3CN (2 mL), 4- chlorophenylisothiocyanate (22 mg, 0.13 mmol) was added. After being stirred at room temperature for 30 min, the mixture was purified by HPLC to give the titled compound (6 mg). MS 489.0 and 491.0 (M+H, Cl pattern).

Reference： [1]Patent: WO2006/63113,2006,A2 .Location in patent: Page/Page column 118-119
[2]Patent: WO2006/63293,2006,A2 .Location in patent: Page/Page column 49

26
[ 378784-00-0 ]
[ 2900-27-8 ]
[ 35264-05-2 ]

Yield	Reaction Conditions	Operation in experiment
	With acetic acid; In methanol; ethyl acetate;	B. N-BOC-alpha-phenylglycine, methyl ester (1.2 g) is dissolved in methanol (50 ml) containing acetic acid (1 ml). 5% rhodium on aluminum powder (0.60 g) is added and the mixture shaken under 50 psi hydrogen for about 18 hours. The mixture is filtered, evaporated in vacuo, and the residue taken up into ethyl acetate. The organic solution is washed with water, saturated sodium bicarbonate solution, water, brine, dried over magnesium sulfate, filtered, evaporated in vacuo to give N-BOC-alpha-cyclohexylglycine, methyl ester.

Reference： [1]Patent: US5866685,1999,A

27
[ 929281-91-4 ]
[ 2900-27-8 ]
[ 929281-92-5 ]

Yield	Reaction Conditions	Operation in experiment
58%	With 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine In dichloromethane at 20℃; for 72h;	89.b To a stirred CH2CI2 solution (0.1 M, 7.5 mL) of Λ/-(4-aminobutyl)-2-chloro-4- fluorobenzenesulfonamide (0.25 g, 0.89 mmol) were added EDC hydrogen chloride (0.19 g, 0.98 mmol), HOBt (0.13 g, 0.98 mmol), Λ/-Boc-phenylglycine (0.22 g, 0.89 mmol) and triethylamine (0.3 mL, 2.23 mmol). The resulting solution was stirred at RT for 3 days, after which time 1 N HCI solution was added to the mixture. The layers were separated and the organic portion was washed with 5% aq. NaHCO3 and brine. The organic phase was dried over Na2SO4, filtered and concentrated to a residue, which was purified by flash column chromatography (SiO2, 50% ethyl acetate/hexanes). The title compound was isolated as a white solid in 58% yield (0.27 g); LCMS (m/z): 514 (M+H).

Reference： [1]Current Patent Assignee: GLAXOSMITHKLINE PLC - WO2007/30761, 2007, A2 Location in patent: Page/Page column 36; 92

28
[ 878798-89-1 ]
[ 2900-27-8 ]
[ 878798-90-4 ]

Yield	Reaction Conditions	Operation in experiment
85%	With 4-methyl-morpholine; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; 3-hydroxy-3,4-dihydrobenzotriazine-4-one In dichloromethane at 20℃;	60.c To a dichloromethane solution of Λ/-(3-aminopropyl)-4-fluoro-2- (trifluoromethyl)benzenesulfonamide (200mg, 0.594 mmol) was added (2S)-([(1 ,1 - dimethylethyl)oxy]carbonyl}amino)(phenyl)ethanoic acid (179mg, 0.713mmol), HOOBT (1.2 mg, 0.007 mmol), and NMM (0.3ml, 2.97mmol). The mixture was stirred several minutes whereupon EDCHCI (137mg, 0.713 mmol) was added. The reaction mixture was stirred overnight at RT. The solution was washed with 10% citric acid and brine, dried (MgSO4), filtered and concentrated to a solid. Purification by silica gel column chromatography (30%-90% ethyl acetate/hexane) gave the product in 85% yield (269mg): MS (m/z): 533 (M+H).

Reference： [1]Current Patent Assignee: GLAXOSMITHKLINE PLC - WO2006/29210, 2006, A2 Location in patent: Page/Page column 71

29
[ 2900-27-8 ]
[ 13143-47-0 ]
[ 678179-38-9 ]

Yield	Reaction Conditions	Operation in experiment
	With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; In water; N,N-dimethyl-formamide;	Part A. <strong>[13143-47-0]1-(4-Aminophenyl)-1H-pyridin-2-one</strong> (0.59 g, 3.19 mmol) and Boc-DL-PHG-OH (0.80 g, 3.19 mmol) were stirred in dry DMF (8 mL) at RT under N2. HATU (1.33 g, 3.51 mmol, 1.1 eq) was added, followed by the addition of DIEA (1.12 g, 6.38 mmol, 2.0 eq). The resulting mixture was stirred at rt for 3 h. H2O was added, and the mixture was extracted with EtOAc (2*), washed with H2O and brine, dried over MgSO4, filtered, and concentrated to dryness. The residue was purified by flash column chromatography (silica gel, CH2Cl2, then CH2Cl2:EtOAc=1:1) to give [4-(2-oxo-2H-pyridin-1-yl)phenylcarbamoyl]phenylmethyl}-carbamic acid tert-butyl ester (1.23 g, yield: 92%). LC/MS-ESI (M+H)+420.4.

Reference： [1]Patent: US2004/77635,2004,A1

30
[ 2900-27-8 ]
[ 62-53-3 ]
[ 329791-72-2 ]

Yield	Reaction Conditions	Operation in experiment
88%	Stage #1: (2S)-2-[(tert-butoxycarbonyl)amino]-2-phenylethanoic acid With O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate; triethylamine at 0℃; for 0.333333h; Stage #2: aniline at 20℃; for 8h;
85%	With dicyclohexyl-carbodiimide In dichloromethane at 20℃; for 16h; Inert atmosphere;	4.2 General procedure for the preparation of carbamates 2a-e General procedure: To a vigorously stirred solution of the relevant (S)-N-Boc-amino acid 1a-e (15.1 mmol) and aniline (1.93 mL, 21.1 mmol) in CH2Cl2 (25 mL) was added DCC (3.43 g, 16.6 mmol) in small portions. The solution was stirred at room temperature for 16 h, filtered on Celite, and then concentrated under vacuum (40 Torr). The crude product was purified by flash chromatography on silica gel (EtOAc/hexane, 4:1) and then by crystallization from heptane, to afford the relevant compounds 2a-e in good yield.
	Stage #1: (2S)-2-[(tert-butoxycarbonyl)amino]-2-phenylethanoic acid With TEA; chloroformic acid ethyl ester In tetrahydrofuran at -15℃; Stage #2: aniline In tetrahydrofuran at 20℃; Further stages.;

With benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate; N-ethyl-N,N-diisopropylamine In dichloromethane at 20℃; for 1.5h;

Reference： [1]Li, Jingyao; Li, Xiaoyang; Wang, Xue; Hou, Jinning; Zang, Jie; Gao, Shuai; Xu, Wenfang; Zhang, Yingjie [Chemical Biology and Drug Design, 2016, p. 574 - 584]
[2]Gavrilov, Konstantin N.; Shiryaev, Alexei A.; Zheglov, Sergey V.; Potapova, Oksana V.; Chuchelkin, Ilya V.; Novikov, Ivan M.; Rastorguev, Eugenie A.; Davankov, Vadim A. [Tetrahedron Asymmetry, 2013, vol. 24, # 7, p. 409 - 417]
[3]Chen, Fubin; Huang, Shi; Zhang, Hui; Liu, Fengying; Peng, Yungui [Tetrahedron, 2008, vol. 64, # 40, p. 9585 - 9591]
[4]Chen, Rui-Jia; Wang, Jun-Jie; Han, Li; Gu, Yu-Cheng; Xu, Zhi-Ping; Cheng, Jia-Gao; Shao, Xu-Sheng; Xu, Xiao-Yong; Li, Zhong [Journal of Heterocyclic Chemistry, 2021, vol. 58, # 7, p. 1429 - 1436]

31
[ 2900-27-8 ]
[ 227940-72-9 ]
[ 1018901-79-5 ]

Yield	Reaction Conditions	Operation in experiment
	Stage #1: (2S)-2-[(tert-butoxycarbonyl)amino]-2-phenylethanoic acid With TEA; chloroformic acid ethyl ester In tetrahydrofuran Stage #2: tert-Butyl 3,7-diazabicyclo[3.3.1]nonane-3-carboxylate In tetrahydrofuran Further stages.;

Reference： [1]Liu, Jie; Yang, Zhigang; Wang, Zhen; Wang, Fei; Chen, Xiaohong; Liu, Xiaohua; Feng, Xiaoming; Su, Zhishan; Hu, Changwei [Journal of the American Chemical Society, 2008, vol. 130, # 17, p. 5654 - 5655]

32
[ 1059182-78-3 ]
[ 2900-27-8 ]
((S)-{(3,4-dimethoxy-phenyl)-[2-(4-trifluoromethyl-phenyl)-ethyl]-carbamoyl}-phenyl-methyl)-carbamic acid tert-butyl ester [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
100%	With 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 0℃; for 4h;	173.3 Step 3: ((S)-{(3,4-Dimethoxy-phenyl)-[2-(4-trifluoromethyl-phenyl)-ethyl]-carbamoyl}-phenyl-methyl)-carbamic acid tert-butyl ester To a 0° C. solution of 3.25 g (10 mmol) (3,4-dimethoxy-phenyl)-[2-(4-trifluoromethyl-phenyl)-ethyl]-amine and 2.8 g (11 mmol) Boc-L-alpha-phenylglycine in 50 ml dichloromethane under argon, was added 2.1 g (11 mmol) 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride. The mixture was stirred at 0° C. for 4 hours. The solution was washed once with 50 ml of a sat. NaHCO3 solution and once with 50 ml water. The combined extracts were dried over Na2SO4, filtered and concentrated in vacuo. The crude oil was purified with flash column chromatography on silica eluding with a gradient formed from heptane and ethylacetate to provide 5.6 g (100%) of the title compound as a yellow gum. MS (m/e): 558.8 [M+H]+.

Reference： [1]Current Patent Assignee: ROCHE HOLDING AG - US2009/36422, 2009, A1 Location in patent: Page/Page column 75

33
[ 1201194-57-1 ]
[ 2900-27-8 ]
[ 1201194-58-2 ]

Yield	Reaction Conditions	Operation in experiment
75%	With 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 0 - 20℃; Inert atmosphere;	21.c.3 To a 0° C. solution of 35 mg (0.15 mmol) (3,4-dimethyl-phenyl)-[2-(5-methyl-pyridin-2-yl)-ethyl]-amine and 40.4 mg (0.16 mmol) Boc-L-alpha-phenylglycine in 540 uL dichloromethane under argon, was added 31.4 mg (0.16 mmol) 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride. The mixture was stirred at 0° C. for 3 hours then at ambient temperature overnight. The solution was washed once with a sat. NaHCO3 solution (3 mL) and once with water (3 mL). The combined extracts were dried over Na2SO4, filtered and concentrated in vacuo. The crude oil was purified with flash column chromatography on silica eluting with a gradient formed from heptane and ethylacetate to provide 0.052 g (75%) of the title compound as an oil. MS (m/e): 474.3 [M+H]+.

Reference： [1]Current Patent Assignee: ROCHE HOLDING AG - US2009/312314, 2009, A1 Location in patent: Page/Page column 24

34
[ 593-51-1 ]
[ 2900-27-8 ]
[ 1033883-20-3 ]

Yield	Reaction Conditions	Operation in experiment
99%	Stage #1: methylamine hydrochloride; (2S)-2-[(tert-butoxycarbonyl)amino]-2-phenylethanoic acid With benzotriazol-1-ol; N-ethyl-N,N-diisopropylamine In dichloromethane; N,N-dimethyl-formamide at 0℃; for 0.166667h; Stage #2: With 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane; N,N-dimethyl-formamide at 25℃; for 18h;	60.A To a solution of (S)-2-(tert-butoxycarbonylamino)-2-phenylacetic acid (1.00 g, 3.98 mmol) in DMF (5 mL) and methylene chloride (5 mL) was added methylamine hydrochloride (403 mg, 5.97 mmol), HOBt (645 mg, 4.78 mmol), and Hunig's Base (1.73 mL, 9.95 mmol) and the resulting solution stirred at 0° C. for 10 minutes. EDCI (916 mg, 4.78 mmol) was added and the reaction stirred at 25° C. for 18 hours. The mixture was concentrated in vacuo, the resulting residue was diluted with ethyl acetate (45 mL), brine (10 mL), and 5% H3PO4 aqueous solution (10 mL), and the layers were separated. The organic layer was washed with 5% H3PO4 aqueous solution (10 mL), twice with saturated aqueous sodium bicarbonate solution (15 mL), water (15 mL), and brine (15 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated in vacuo to afford the title compound as a light colored solid. The crude material was taken on directly to the next step. (1.04 g, 99% yield) MS (ESI+) m/z=265 (M+H)+

Reference： [1]Current Patent Assignee: ABBVIE INC - US2010/29686, 2010, A1 Location in patent: Page/Page column 74

35
[ 104641-60-3 ]
[ 2900-27-8 ]
[ 1379513-77-5 ]

Yield	Reaction Conditions	Operation in experiment
64%	With benzotriazol-1-ol; dicyclohexyl-carbodiimide; In tetrahydrofuran; at 20℃; for 15h;	To a solution of 2-(tert-butoxycarbonylamino)-2-phenylacetic acid (13)(400 mg, 1.59 mmol) in THF (20 ml), (R)-l-methylpyrrolidin-3-ol (193 mg, 1.91 mmol), N,N'-methanediylidenedicyclohexanamine (394 mg, 1.91 mmol) and lH-benzo[d][ l,2,3]triazol-l-ol (258 mg, 1.91 mmol) were added. The reaction was stirred at RT for 15h then the solvent was evaporated. The residue was taken up with DCM, the insoluble was filtered off and the clear solution was washed twice with aq. Na2CO3 and brine, dried over Na2SO4 and evaporated to obtain (R)-l-methylpyrrolidin-3-yl2-(tert-butoxycarbonylamino)-2-phenylacetate (340 mg; 64% yield).
64%	With benzotriazol-1-ol; dicyclohexyl-carbodiimide; In tetrahydrofuran; at 20℃; for 15h;	To a solution of 2-(tert-butoxycarbonylamino)-2-phenylacetic acid (I3) (400 mg, 1.59 mmol) in THF (20 ml), were added (R)-1-methylpyrrolidin-3-ol (193 mg, 1.91 mmol), N,N'-methanediylidenedicyclohexanamine (394 mg, 1.91 mmol), and 1H-benzo[d][1,2,3]triazol-1-ol (258 mg, 1.91 mmol). The reaction was stirred at RT for 15, hours, and then the solvent was evaporated. The residue was taken up with DCM, the insoluble was filtered off, and the clear solution was washed twice with aq. Na2CO3 and brine, dried over Na2SO4 and evaporated to obtain (R)-1-methylpyrrolidin-3-yl 2-(tert-butoxycarbonylamino)-2-phenylacetate (340 mg; 64% yield).

Reference： [1]Patent: WO2012/69275,2012,A1 .Location in patent: Page/Page column 71
[2]Patent: US2012/134934,2012,A1 .Location in patent: Page/Page column 33-34

36
[ 2900-27-8 ]
[ 943322-87-0 ]

Reference： [1]Organic and Biomolecular Chemistry,2012,vol. 10,p. 5613 - 5619

37
[ 2900-27-8 ]
[ 110143-62-9 ]

Reference： [1]Organic and Biomolecular Chemistry,2012,vol. 10,p. 5613 - 5619

38
[ 2900-27-8 ]
[ 137102-30-8 ]

Reference： [1]Organic and Biomolecular Chemistry,2012,vol. 10,p. 5613 - 5619

39
[ 2900-27-8 ]
[ 60719-84-8 ]
[ 1401206-34-5 ]

Reference： [1]Bioorganic and medicinal chemistry letters,2012,vol. 22,p. 5942 - 5947,6

40
[ 2900-27-8 ]
[ 60719-84-8 ]
[ 1401206-59-4 ]

Reference： [1]Bioorganic and medicinal chemistry letters,2012,vol. 22,p. 5942 - 5947,6

41
[ 373-44-4 ]
[ 2900-27-8 ]
[ 1412423-31-4 ]

Yield	Reaction Conditions	Operation in experiment
94%	With 2,4,6-trimethyl-pyridine; benzotriazol-1-ol; O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate In N,N-dimethyl-formamide at 0℃; for 2h;	4.11.1 Compound 16a HOBt (104 mg, 0.77 mmol), HBTU (292 mg, 0.77 mmol) and Sym-collidine (169.1 μL, 1.28 mmol) were sequentially added to a stirred solution of commercially available 15a (46.2 mg, 0.32 mmol) and N-Boc-(S)-2-Phenylglycine (200.9 mg, 0.80 mmol) in dry DMF (2 mL) at 0 °C. The reaction mixture was left stirring for 2 h and then, after reaction completion, the mixture was diluted with EtOAc (20 mL) and washed with a saturated solution of ammonium chloride (3 × 20 mL), saturated solution of sodium bicarbonate (3 × 20 mL) and brine (1 × 20 mL. The organic layers were dried over Na2SO4, and then the solvent was removed under reduced pressure. The residue was purified by Biotage flash chromatography, eluant conditions: from 1% of MeOH and 99% of CH2Cl2 to 10% of MeOH and 90% of CH2Cl2. Yield 94% (183 mg, MW 610.80, 0.30 mmol) of pure 16a. Analytical characterization: 1H NMR (400 MHz, CDCl3):δ: 7.38-7.25 (m, 10H), 5.76 (m, 2H), 5.25 (m, 2H), 3.32 (bs, 1H), 3.23 (m, 2H), 3.13 (bs, 1H), 1.57 (s, 4H), 1.42 (m, 18H), 1.21 (d, J = 11.2 Hz, 6H); 13C NMR (100 MHz, CDCl3): δ: 129.0, 128.9, 128.3, 127.2, 39.7, 39.7, 29.2, 28.8, 28.3, 26.4. ESI-MS: m/z 611.4 [M+H]+.

Reference： [1]Manzoni, Leonardo; Belvisi, Laura; Potenza, Donatella; Vasile, Francesca; Seneci, Pierfausto; Bianchi, Aldo; Drago, Carmelo; De Matteo, Marilenia; Ferrante, Luca; Scolastico, Carlo; Timpano, Gabriele; Rizzo, Vincenzo; Conti, Annalisa; Perego, Paola; Mastrangelo, Eloise; Servida, Federica [Bioorganic and medicinal chemistry, 2012, vol. 20, # 22, p. 6687 - 6708,22]

42
[ 4246-51-9 ]
[ 2900-27-8 ]
[ 1412423-32-5 ]

Yield	Reaction Conditions	Operation in experiment
94%	With 2,4,6-trimethyl-pyridine; benzotriazol-1-ol; O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; In N,N-dimethyl-formamide; at 0℃; for 2h;	HOBt (73 mg, 0.54 mmol), HBTU (204.8 mg, 0.54 mmol) and Sym-collidine (118.9 mL, 0.90 mmol) were sequentially added to a stirred solution of commercially available 15b (50 mg, 0.227 mmol) and N-Boc-(S)-2-Phenylglycine (142 mg, 0.567 mmol) in dry DMF (2 mL) at 0 C. The reaction mixture was left stirring for 2 hours and then, after reaction completion, the mixture was diluted with EtOAc (20 mL) and washed with a saturated solution of ammonium chloride (3 x 20 mL), saturated solution of sodium bicarbonate (3 x 20 mL) and brine (1 x 20 mlL. The organic layers were dried over Na2SO4, and then the solvent was removed under reduced pressure. The residue was purified by BiotageTM flash chromatography, eluant conditions: from 1% of MeOH and 99% of CH2Cl2 to 10% of MeOH and 90% of CH2Cl2. Yield 94 % (146 mg, MW 686.85, 0.212 mmol) of pure 16b. Analytical characterization: 1H-NMR (400 MHz, CDCl3): d: 7.39-7.28 (m, 10H), 6.55 (bs, 2H), 5.94 (bs, 2H), 5.10 (bs, 2H), 3.59-3.31 (m, 16H), 1.70 (t, J = 6.0 Hz, 4H), 1.42 (s, 18H); 13C-NMR (100 MHz, CDCl3): d: 170.3, 138.9, 128.8, 128.1, 127.2, 79.8, 70.4, 70.1, 69.7, 38.1, 28.7, 28.3. ESI-MS: m/z 687.6 [M+H]+, 709.5 [M+Na]+.

Reference： [1]Bioorganic and medicinal chemistry,2012,vol. 20,p. 6687 - 6708,22

43
[ 1412423-29-0 ]
[ 2900-27-8 ]
[ 1412423-33-6 ]

Yield	Reaction Conditions	Operation in experiment
88%	With 2,4,6-trimethyl-pyridine; benzotriazol-1-ol; O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate In N,N-dimethyl-formamide at 0℃; for 2h;	Compound 16c. HOBt (23 mg, 0.17 mmol), HBTU (64.5 mg, 0.17 mmol) and Sym-collidine (35.7 mL, 0.27 mmol) were sequentially added at 0 °C to a stirred solution of commercially available 3,4-bis-(4-amino-butylamino)-cyclobut-3-ene-1,2-dione (17 mg, 0.068 mmol) and N-Boc-(S)-2-Phenylglycine (43 mg, 0.17 mmol) in dry DMF (0.5 mL). The reaction mixture was left stirring and monitored by LC-MS. After reaction completion, the mixture was diluted with EtOAc and sequentially washed with a saturated aqueous solution of NH4Cl, saturated aqueous solution of sodium bicarbonate, and brine. The organic layer was dried over Na2SO4, and then the solvent removed under reduced pressure. The residue was purified by BiotageTM flash chromatography, eluant conditions: from 1% of MeOH and 99% of CH2Cl2 to 10% of MeOH and 90% of CH2Cl2. Yield 88 % (43 mg, MW 720.87, 0.060 mmol) of pure 16c. Analytical characterization: 1H-NMR (400 MHz, CD3OD): d: 7.41-7.31 (m, 10H), 5.11 (bs, 2H), 3.56 (bs, 4H), 3.30-3.19 (m, 4H), 1.55 (bs, 8H), 1.44 (s, 18H); 13C-NMR (100 MHz, CD3OD): d: 128.3, 127.8, 127.0, 43.4, 38.7, 28.1, 27.3, 25.8. ESI-MS: m/z 721.1 [M+H]+.

Reference： [1]Manzoni, Leonardo; Belvisi, Laura; Potenza, Donatella; Vasile, Francesca; Seneci, Pierfausto; Bianchi, Aldo; Drago, Carmelo; De Matteo, Marilenia; Ferrante, Luca; Scolastico, Carlo; Timpano, Gabriele; Rizzo, Vincenzo; Conti, Annalisa; Perego, Paola; Mastrangelo, Eloise; Servida, Federica [Bioorganic and medicinal chemistry, 2012, vol. 20, # 22, p. 6687 - 6708,22]

44
[ 1412423-30-3 ]
[ 2900-27-8 ]
[ 1412423-34-7 ]

Yield	Reaction Conditions	Operation in experiment
83%	With 2,4,6-trimethyl-pyridine; benzotriazol-1-ol; O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate In N,N-dimethyl-formamide at 0℃; for 2h;	Compound 16d. HOBt (23 mg, 0.17 mmol), HBTU (64.5 mg, 0.17 mmol) and Sym-collidine (35.7 mL, 0.27 mmol) were sequentially added at 0 °C to a stirred solution of commercially available deca-4,6-diynedioic acid bis-[(2-amino-ethyl)-amide] (17 mg, 0.068 mmol) and N-Boc-(S)-2-Phenylglycine (43 mg, 0.17 mmol) in dry DMF (3 mL). The reaction mixture was left stirring and monitored by LC-MS. After reaction completion, the mixture was diluted with EtOAc and sequentially washed with a saturated aqueous solution of NH4Cl, saturated aqueous solution of sodium bicarbonate, and brine. The organic layer was dried over Na2SO4, and then the solvent removed under reduced pressure. The residue was purified by BiotageTM flash chromatography, eluant conditions: from 1% of MeOH and 99% of CH2Cl2 to 10% of MeOH and 90% of CH2Cl2. Yield 83 % (42 mg, MW 744.90, 0.056 mmol) of pure 16d. Analytical characterization: 1H-NMR (400 MHz, CDCl3): d: 7.32-7.19 (m, 10H), 6.81 (bs, 2H), 5.73 (d, J = 6.4 Hz, 2H), 5.08 (bs, 2H), 3.32-3.19 (m, 8H), 2.43 (m, 4H), 2.19 (m, 4H), 1.33 (s, 18H); 13C-NMR (100 MHz, CDCl3): d: 171.3, 129.0, 128.3, 127.2, 80.2, 66.2, 59.0, 41.0, 38.7, 34.8, 28.3, 16.0. ESI-MS: m/z 745.6 [M+H]+.

Reference： [1]Manzoni, Leonardo; Belvisi, Laura; Potenza, Donatella; Vasile, Francesca; Seneci, Pierfausto; Bianchi, Aldo; Drago, Carmelo; De Matteo, Marilenia; Ferrante, Luca; Scolastico, Carlo; Timpano, Gabriele; Rizzo, Vincenzo; Conti, Annalisa; Perego, Paola; Mastrangelo, Eloise; Servida, Federica [Bioorganic and medicinal chemistry, 2012, vol. 20, # 22, p. 6687 - 6708,22]

45
[ 2900-27-8 ]
[ 134179-38-7 ]
[ 1412423-57-4 ]

Yield	Reaction Conditions	Operation in experiment
74%	With 2,4,6-trimethyl-pyridine; benzotriazol-1-ol; O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate In N,N-dimethyl-formamide at 0℃; for 2h;	4.15.1 Compound 16e HOBt (81 mg, 0.6 mmol), HBTU (227.5 mg, 0.6 mmol) and Sym-collidine (132.1 μL, 1 mmol) were sequentially added to a stirred solution of commercially available 15e (110 mg, 0.503 mmol) and N-Boc-(S)-2-Phenylglycine (158 mg, 0.63 mmol) in dry DMF (3 mL) at 0 °C . The reaction mixture was left stirring and monitored by LC-MS. After reaction completion, the mixture was diluted with EtOAc (20 mL) and sequentially washed with 5% aqueous citric acid (20 mL), saturated aqueous sodium bicarbonate (20 mL) and brine (2 × 20 mL). The organic layer was dried over Na2SO4, and then the solvent was removed under reduced pressure. The residue was purified by Biotage flash chromatography, eluant conditions: from 1% of MeOH and 99% of CH2Cl2 to 10% of MeOH and 90% of CH2Cl2. Yield 74% (167 mg, MW 51.53, 0.37 mmol) of pure 16e. Analytical characterization: 1H NMR (400 MHz, CDCl3): δ: 7.32.7.20 (m, 5H), 6.28 (bs, 1H), 5.77 (bs, 1H), 5.07 (bs, 1H), 3.6-3.28 (m, 16H), 1.35 (s, 9H); 13C NMR (100 MHz, CDCl3): δ: 129.0, 128.3, 127.2, 70.7, 70.6, 70.5, 70.3, 70.0, 69.6, 68.8, 58.5, 50.7, 39.6, 28.3. ESI-MS: m/z 452.5 [M+H]+, 474.5 [M+Na]+.

Reference： [1]Manzoni, Leonardo; Belvisi, Laura; Potenza, Donatella; Vasile, Francesca; Seneci, Pierfausto; Bianchi, Aldo; Drago, Carmelo; De Matteo, Marilenia; Ferrante, Luca; Scolastico, Carlo; Timpano, Gabriele; Rizzo, Vincenzo; Conti, Annalisa; Perego, Paola; Mastrangelo, Eloise; Servida, Federica [Bioorganic and medicinal chemistry, 2012, vol. 20, # 22, p. 6687 - 6708,22]

46
[ 762-75-4 ]
[ 2935-35-5 ]
[ 2900-27-8 ]

Yield	Reaction Conditions	Operation in experiment
	With sodium hydroxide In tetrahydrofuran; water at 20℃; for 4h;	General procedure: A suspension of amino acid derivative (5 mmol) was dissolved ina mixture of tetrahydrofuran (50 mL) and water (20 mL). 1 N NaOH(6 mL) was added followed by adding 1.1 g tert-butoxycarbonyl(5 mmol) dropwise at room temperature. After stirring for 4 h,the tetrahydrofuran was evaporated in vacuum from the reaction mixture. The residue was added ethyl acetate (50 mL) and 5% citricacid (30 mL). The organic layer was separated, washed with water(20 mL), dried with anhydrous Na2SO4 and rotary evaporated to dryness. Crude residue was used into next reaction without purification.

Reference： [1]Shang, Ruofeng; Liu, Yu; Xin, Zhijun; Guo, Wenzhu; Guo, Zhiting; Hao, Baocheng; Jianping, Liang [European Journal of Medicinal Chemistry, 2013, vol. 63, p. 231 - 238]

47
[ 2900-27-8 ]
[ 7517-19-3 ]
(S)-N-[(S)α-phenyl-N-(tert-butoxycarbonyl)glycinyl]leucine methyl ester [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
83%	Stage #1: (2S)-2-[(tert-butoxycarbonyl)amino]-2-phenylethanoic acid With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 0℃; for 0.5h; Stage #2: methyl (L)-leucinate hydrochloride With N-ethyl-N,N-diisopropylamine In dichloromethane for 7h;	Methyl (pyrazine-2-carbonyl)-L-phenylalaninate (B1) General procedure: At 0 °C, to a solution of pyrazinecarboxylic acid (0.7 g, 5.6 mmol) in anhydrous DCM were added HOBT (0.9 g, 6.8 mmol) and EDCI (1.3 g, 6.8 mmol). After 30 min, L-phenylalanine methyl ester hydrochloride (1.1 g, 5.1 mmol) and DIEA (0.9 g, 7.0 mmol) were added. Stirring was continued for 7 h and then the DCM solution washed with 1 N HCl, saturated NaHCO3 and brine, dried over MgSO4, and evaporated under vacuum. The crude product was purified by flash column chromatography to give desired compound B1 (1.36 g, 80% yield) as the colorless oil.
	Stage #1: (2S)-2-[(tert-butoxycarbonyl)amino]-2-phenylethanoic acid; methyl (L)-leucinate hydrochloride With dmap; benzotriazol-1-ol; triethylamine In dichloromethane at 0℃; for 0.25h; Stage #2: With 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 0 - 20℃; for 14h;
	With ethylene dichloride hydrochloride; C₆H₅N₃O*Cl^(1-); N-ethyl-N,N-diisopropylamine In dichloromethane at 21 - 23℃;

Reference： [1]Marapaka, Anil Kumar; Sankoju, Priyanka; Zhang, Guozhen; Ding, Yongzheng; Ma, Chunhua; Pillalamarri, Vijaykumar; Sudhakar, Renu; Reddi, Bharati; Sijwali, Puran Singh; Zhang, Yingjie; Addlagatta, Anthony [Chinese Chemical Letters, 2022, vol. 33, # 5, p. 2550 - 2554]
[2]Pan, Huili; Yang, Kanghui; Zhang, Jian; Xu, Yingying; Jiang, Yuqi; Yuan, Yumei; Zhang, Xiaopan; Xu, Wenfang [Journal of Enzyme Inhibition and Medicinal Chemistry, 2013, vol. 28, # 4, p. 717 - 726]
[3]Shugrue, Christopher R.; Featherston, Aaron L.; Lackner, Rachel M.; Lin, Angela; Miller, Scott J. [Journal of Organic Chemistry, 2018, vol. 83, # 8, p. 4491 - 4504]

48
[ 2900-27-8 ]
[ 29833-32-7 ]
[ 1608150-81-7 ]

Reference： [1]Organic and Biomolecular Chemistry,2014,vol. 12,p. 3288 - 3302

49
C₁₃H₁₇NO₄*C₁₅H₂₂N₂O [ No CAS ]
[ 2900-27-8 ]
(1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
1: 100% 2: 15.9 g	With sodium hydroxide In water at 20℃;	4 Example 5 Preparation of levomilnacipran free base ((1S,2R)-cis-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide) Example 5 Preparation of levomilnacipran free base ((1S,2R)-cis-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide) Trimethyl silyl chloride (9.7 ml, 76.7 mmol) is added dropwise to a solution of the compound of Example 4 (15.7 g, 63.9 mmol) in methyl-tert-butyl ether (150 ml) and 2-propanol (25 ml), and the formation of a white solid occurs. The mixture is stirred for 30 minutes, cooled to 20°C and filtered. The filtered solid is washed with 35 ml of cold methyl-tert-butyl ether and dried under vacuum for 20 hours. 17.2 g of levomilnacipran hydrochloride (60.81 mmol, yield 95%) are obtained.2-propanol (44 ml) is added to the obtained product (17.2 g, 60,81 mmol) and it is heated to 75°C until complete dissolution, cooled to RT and the formation of a white solid occurs. It is filtered and washed with cold 2-propanol (6 ml), and 13.5 (g) of the product are obtained.50 ml of methyl-tert-butyl ether are added to the mother liquors and it is stirred at room temperature for 30 minutes, then left to decant, filtered and washed with cold methyl-tert-butyl ether. 2.72 (g) of the product are obtained, that combined with the previous one gives an overall yield of 89.6%,

Reference： [1]Current Patent Assignee: P&R SPA - WO2015/92502, 2015, A1 Location in patent: Page/Page column 7; 8

50
[ 2900-27-8 ]
[ 15028-39-4 ]
Boc-Phg-Phg-OMe [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
88%	With 2,6-dimethylpyridine; 1-[(1-(cyano-2-ethoxy-2-oxoethylidenaminooxy)dimethylamino-morpholino)]-uronium hexafluorophosphate In water at 20℃; for 4h; Green chemistry;

Reference： [1]Gabriel, Christopher M.; Keener, Megan; Gallou, Fabrice; Lipshutz, Bruce H. [Organic Letters, 2015, vol. 17, # 16, p. 3968 - 3971]

51
[ 2900-27-8 ]
[ 189440-33-3 ]
C₂₇H₃₃N₅O₃ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
91%	Stage #1: (2S)-2-[(tert-butoxycarbonyl)amino]-2-phenylethanoic acid With benzotriazol-1-ol; O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate; N-ethyl-N,N-diisopropylamine In dichloromethane; N,N-dimethyl-formamide at 20℃; for 0.166667h; Inert atmosphere; Stage #2: (2-aminoethyl)bis(2-pyridylmethyl)amine In dichloromethane; N,N-dimethyl-formamide at 20℃; for 24h; Inert atmosphere;	N-Boc (S)-PheGly (160 mg, 0.637 mmol, 1.2 eq),TBTU (225 mg, 0.692 mmol, 1.3 eq), HOBt (122 mg, 0.903 mmol, 1.7 eq) and dryDIPEA (0.29 mL, 3 eq) were dissolved under nitrogen atmosphere in dry CH2Cl2 (5 mL) and dry DMF (2 mL). After 10 minutes a solution of compound 14[1](130 mg, 0.531 mmol, 1 eq)in dry CH2Cl2 (5 mL) was added. The reaction mixture was stirred atrt for 24 hours (TLC, hexane/EtOAc 2/8 and CH2Cl2/MeOH 95/5). After 24 hours the solventwas removed under reduced pressure, the crude was diluted with CH2Cl2 (20 mL) and washed with saturated aqueous NH4Cl (2 x 20mL), saturated aqueous NaHCO3 (2 x 20mL) and brine (20mL).The collected organic layers were dried with Na2SO4,filtered and the solvent was removed under reduced pressure. The crude product(298 mg) was purified by flash chromatography on basic alumina (AcOEt/Hexane 7/3),yielding pure compound 15a,b asa white solid (234 mg, 0.477mmol).Yield: 91%[1] Fukuoka, S.; Kida, T.; Nakajima, Y.; Tsumagari,T.; Watanabe, W.; Inaba, Y.; Mori, A.; Matsumura, T.; Nakano, Y.; Takeshita, K.Tetrahedron 2010, 66, 1721. 1H NMR(400 MHz, CDCl3): δ(ppm) 8.59 (d, 2H, J = 4.5 Hz, H8), 8.26 (bs,1H, NH-Boc), 7.61 (t, 2H, J = 7.7 Hz, H6), 7.49 (d, 2H, J = 6.3 Hz, H9),7.36-7.29 (m, 3H, H10, H11), 7.21 (m, 4H, H5, H7), 6.06 (bs, 1H, NH), 5.31 (s, 1H, H1), 3.91(s, 4H, H4), 3.45 (m, 1H, H2), 3.30 (m, 1H, H2), 2.82 (s, 2H, H3), 1.44 (s, 9H,H12).13C NMR (100.6 MHz, CDCl3): 169.9, 158.8, 155.0, 149.0, 139,4, 136.6,128.7, 127.9, 127.1, 123.1, 122.2, 79.6, 59.7, 58.4, 52.2, 37.8, 28.3.

Reference： [1]Manzoni, Leonardo; Gornati, Davide; Manzotti, Mattia; Cairati, Silvia; Bossi, Alberto; Arosio, Daniela; Lecis, Daniele; Seneci, Pierfausto [Bioorganic and Medicinal Chemistry Letters, 2016, vol. 26, # 19, p. 4613 - 4619]

52
[ 5824-40-8 ]
[ 2900-27-8 ]
tert-butyl (S)-(2-oxo-1-phenyl-2-(tritylamino)ethyl)carbamate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
93%		General procedure: At first,EDCI (1.22 g, 5.5 mmol) was added into a stirring solution of(tert-butoxycarbonyl)leucine 10 (1.16 g, 5.0 mmol) and DMAP(210 mg, 1.5 mmol) in dry dichloromethane (15 mL). The mixturewas stirred for 15 min and then cooled to 0 C. Triphenylmethanamine11a (1.04 g, 4 mmol) was added to the mixtureand stirred at the same temperature for 30 min. The resulting solutionwas stirred at room temperature until complete consumptionof triphenylmethanamine (monitored by TLC). The reaction wasquenched with water (50 mL) and extracted with dichloromethane(3 50 mL). The combined organic layers were washed with saturatedbrine solution (30 mL), followed by drying over Na2SO4 andevaporation in vacuo. The crude product was purified by columnchromatography to give pure tert-butyl (S)-(4-methyl-1-oxo-1-(tritylamino)pentan-2-yl)carbamate 12a.

Reference： [1]Tetrahedron Asymmetry,2016,vol. 27,p. 1121 - 1132

53
[ 2033-24-1 ]
[ 2900-27-8 ]
(R)-2-(2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-yl)-1-phenylethylcarbamic acid tert-butyl ester [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
79%	Stage #1: cycl-isopropylidene malonate; (2S)-2-[(tert-butoxycarbonyl)amino]-2-phenylethanoic acid With dmap; dicyclohexyl-carbodiimide In dichloromethane at 0 - 10℃; Stage #2: With sodium tetrahydroborate; acetic acid at 0 - 10℃;	2.2 (2) A mixture of (S)-2-(tert-butoxycarbonylamino)-2-phenylacetic acid (150g, 0.59mol), 4-dimethylaminopyridine (130g, 1.06mol), Meldrum's acid (102g, 0.71mol), N,N-dicyclohexylcarbodiimide (185g, 0.89mol) was dissolved in methylene chloride (1.5 L), maintaining the temperature of the reaction system was added dropwise at 0-10 deg. C. The filtrate was washed with 1N HCl (0.5 L * 3), washed with water (0.5 L * 1), and washed with saturated brine (0.5 L * 1), and used directly in the next reaction. The organic phase was cooled to 0-10 ° C, acetic acid (214g, 3.56mol) was added, sodium borohydride (67g, 1.78mol) was added in portions and the temperature was maintained between 0 and 10 ° C. The solution was washed with 1N HCl (0.5 L * 3), washed with water (0.5 L * 1), saturated brine (0.5 L * 1), and washed with saturated brine (0.5 L), and concentrated to give 172g of a yellow solid in 79 % yield.

Reference： [1]Current Patent Assignee: ASTATECH CHENGDU BIOPHARM - CN104592163, 2016, B Location in patent: Paragraph 0052; 0053

54
[ 20691-89-8 ]
[ 2900-27-8 ]
(1-methyl-4-piperidyl)methyl 2-(tert-butoxycarbonylamino)-2-phenyl-acetate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
1.96 g		A mixture of 2-((tert-butoxycarbonyl)amino)-2-phenylacetic acid (1.0 g, 3.98 mmol), N,N'-dicyclohexylcarbodiimide (1.64 g, 7.97 mmol) and 1- hydroxybenzotriazole hydrate (1.08 g, 7.97 mmol) in THF (25 mL) was stirred at room temperature. After one hour a solution of (l-methyl-4-piperidyl)methanol (0.62 g, 4.78 mmol) was added and the mixture was stirred at room temperature for 24 hours. The reaction mixture was filtered through a pad of Celite and concentrated in vacuo. The residue was taken up into EtOAc (30 mL) and washed with saturated aqueous NaHCC"3 solution (2 x 40 mL), then with brine (40 mL). The organic phase was collected, filtered through a phase separator and the solvent was removed in vacuo to give the title compound as a pink gum (1.96 g, Theoretical yield = 1.44 g).LCMS (Method 1): [MH+] = 363 at 2.54 min.

Reference： [1]Patent: WO2016/193240,2016,A1 .Location in patent: Page/Page column 40

55
[ 2900-27-8 ]
[ 702699-84-1 ]

Reference： [1]Tetrahedron Asymmetry,2017,vol. 28,p. 930 - 938
[2]Journal of the American Chemical Society,2018,vol. 140,p. 6545 - 6549

56
[ 702699-84-1 ]
[ 2900-27-8 ]
tert-butyl ((S)-2-(((S)-2-(dimethylamino)-1-phenylethyl)amino)-2-oxo-1-phenylethyl)carbamate [ No CAS ]

Reference： [1]Tetrahedron Asymmetry,2017,vol. 28,p. 930 - 938

57
[ 2900-27-8 ]
[ 167316-27-0 ]
C₃₄H₃₇N₃O₅S [ No CAS ]

Reference： [1]Synthesis,2018,vol. 50,p. 2347 - 2358

58
NH2-Sta-NH(CH2)2Ph hydrochloride [ No CAS ]
[ 2900-27-8 ]
Boc-Phg-Sta-NH(CH2)2Ph [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
75%	With O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃; for 18h;	4.3 General procedure A General procedure: Boc-Leu-Sta-NH(CH2)2Ph (30). A mixture of HCl.NH2-Sta-NH(CH2)2Ph (50 mg, 0.158 mmol), Boc-Leu-OH (35 mg, 0.151 mmol), HBTU (75 mg, 0.196 mmol) and DIPEA (194 μL, 1.11 mmol) in DMF (2 mL) was allowed to stir for 18 h at 20 °C. The reaction mixture was quenched with 10% citric acid solution (1×10 mL) and the desired product extracted into EtOAc (3×15 mL). The organic layers were combined, washed with saturated NaHCO3 (1×20 mL) and brine (1×20 mL), dried with MgSO4 and concentrated in vacuo to obtain the crude residue. The crude residue was purified using a silica chromatography gradient eluting from 100% DCM to 10% MeOH/DCM to obtain Boc-Leu-NH(CH2)2Ph (30) (46 mg, 59%).

Reference： [1]Nguyen, William; Hodder, Anthony N.; de Lezongard, Richard Bestel; Czabotar, Peter E.; Jarman, Kate E.; O'Neill, Matthew T.; Thompson, Jennifer K.; Jousset Sabroux, Helene; Cowman, Alan F.; Boddey, Justin A.; Sleebs, Brad E. [European Journal of Medicinal Chemistry, 2018, vol. 154, p. 182 - 198]

59
[ 2900-27-8 ]
[ 124-63-0 ]
[ 110143-62-9 ]

Yield	Reaction Conditions	Operation in experiment
91%	With N-ethyl-N,N-diisopropylamine; In tetrahydrofuran; at 0 - 10℃;	N-Boc-D- phenylglycinol 17.5g,DIPEA 11.4g, 80ml of tetrahydrofuran was added to the reaction flask.Cool down to 0 C.Methanesulfonyl chloride was added dropwise to the reactor at 10 C.Additional 26 ml of THF was added.After the completion of the reaction, 0.5 N hydrochloric acid (3.6 g of concentrated hydrochloric acid / 67 ml of water) was added to the reactor, stirred at 10 C, and liquid-separated.The organic layer was added to cyclohexane.A white solid was obtained which was dried to give (S)-Boc-phenylglycanol mesylate in a yield of 91%.

Reference： [1]Patent: CN108129400,2018,A .Location in patent: Paragraph 0037; 0041; 0042

60
[ 2900-27-8 ]
3-((2R)-amino-2-phenylethyl)-5-[2-fluoro-3-((2H₃)-methoxy)phenyl]-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-3H-pyrimidine-2,4-dione [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
88%	With potassium carbonate In N,N-dimethyl-formamide at 55℃;	2.3 Step 3 3-((2R)-amino-2-phenylethyl)-5- [2-fluoro-3-((2H3)-methoxy)phenyl]-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-3H-pyrimidine-2,4-dione 19.7g (S) -Boc- phenylglycinol mesylate,16.6 g of 5-[2-fluoro-3-(D3-methoxy)phenyl]-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methylpyrimidine-2, 4-(1H,3H)-dione,Potassium carbonate 13.4 g, 100 ml DMF was added to the reaction flask.The temperature was raised to 55 ° C, and after the reaction was completed, it was cooled to 20 ° C.150 ml of ethyl acetate was added to separate the layers, and the ester layer was left and washed with water.The organic layer was placed in a reaction flask, 11.2 g of methanesulfonic acid was added, and the reaction mixture was warmed to 60 ° C and stirred for 2 hr.The reaction solution was cooled to room temperature, and an aqueous potassium carbonate solution was added thereto to adjust the pH, and the layers were stood still. The ester layer was spun to near dryness, cyclohexane was added over 1 hr, and the slurry was refluxed.Filtered to a white solid with a yield of 88%.

Reference： [1]Current Patent Assignee: ANDIKANG WUXI BIOLOGICAL TECH - CN108129400, 2018, A Location in patent: Paragraph 0054; 0061; 0062

61
[ 2900-27-8 ]
[ 107-14-2 ]
cyanomethyl (S)-2-((tert-butoxycarbonyl)amino)-2-phenylacetate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
78%	With triethylamine In acetonitrile at 0 - 20℃; for 12h;	(8) Cyanomethyl (S)-2-((tert-butoxycarbonyl)amino)-2-phenylacetate (1h) To a stirred solution of (S)-2-((tert-butoxycarbonyl)amino)-2-phenylacetic acid 22 (5 g, 19.90 mmol) in Acetonitrile (100 mL) cooled to 0 °C TEA (8.32 mL, 59.7 mmol) was added after that chloroacetonitrile (2.52 mL, 39.8 mmol) was added dropwise at 0°C slowly raise the temperature up to room temperature and stirring was continued for another 12h. The reaction mixture was quenched with sodium bicorbonate solution and extracted with Ethyl acetate. Take the Ethyl acetate layer and dried over sodium sulphate and concentrated under reduced pressure to get the crude product the crude product was purified by giving the wash of pet ether (2 x 20 mL). Pet-Ether was decanted out and the remaining was dried under vacuum to produce cyanomethyl (S)-2-((tert-butoxycarbonyl)amino)-2-phenylacetate (1h) (4.5 g, 15.51 mmol, 78 % yield). 1H NMR (400 MHz, DMSO-d6): δ 7.39-7.25 (m, 5H), 5.42-5.34 (m, 2H), 4.74-4.70 (m, 2H), 1.43 (s, 9H). MS (ESI): 308.2 as [M+H2O] in +Ve mode.

Reference： [1]Karmakar, Ananta; Basha, Mushkin; Venkatesh Babu; Botlagunta, Murali; Malik, Noormohamed Abdul; Rampulla, Richard; Mathur, Arvind; Gupta, Arun Kumar [Tetrahedron Letters, 2018, p. 4267 - 4271]

62
[ 2900-27-8 ]
[ 368-90-1 ]
tert-butyl (S)-(2-oxo-1-phenyl-2-(2-(4-(trifluoromethyl)phenyl)hydrazineyl)ethyl)carbamate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
95%	Stage #1: (2S)-2-[(tert-butoxycarbonyl)amino]-2-phenylethanoic acid With benzotriazol-1-ol; dicyclohexyl-carbodiimide In tetrahydrofuran at 0℃; for 0.25h; Stage #2: 4-(trifluoromethyl)phenylhydrazine In tetrahydrofuran at 0 - 20℃; for 1.5h;	4.1.1. Synthesis of Hydrazides-General Procedure General procedure: A solution of N-Boc amino acid (0.25 g, 1.43 mmol, 1 equiv.), HOBt (2 equiv.) and DCC (1.2 equiv.)was dissolved in THF (7.5 mL), cooled to 0 C and stirred for 15 min. The solution was treatedwith N-Aryl/Alkyl hydrazine * (1.2 equiv.) before warming to room temperature and stirring fora further 1.5 h. The mixture was then poured into sat. aq. NH4Cl (20 mL) before separating andextracting the aqueous layer with EtOAc (40 mL). The organic layer was further washed with sat.aq. NaHCO3 (20 mL) and then brine (20 mL). The combined organic layers were dried over MgSO4,filtered, concentrated and dried in vacuo. Flash chromatography (DCM/EtOH/NH3 [600:8:1], [400:8:1],[200:8:1]) afforded the desired N-Boc amino acid hydrazides. * When the hydrazine hydrochlorides were used, Et3N (1.2 equiv.) is added to neutralise the salt

Reference： [1]Brown, Alistair K.; Aljohani, Ahmed K.B.; Gill, Jason H.; Steel, Patrick G.; Sellars, Jonathan D. [Molecules, 2019, vol. 24, # 4]

63
1,8-dihydroxy-3-(2-hydroxyethoxy)-6-methylanthracene-9,10-dione [ No CAS ]
[ 2900-27-8 ]
(S)-2-(2-(4,5-dihydroxy-7-methyl-9,10-dioxo-9,10-dihydroanthracen-2-yloxy)ethoxy)-2-oxo-1-phenylethanaminium 2,2,2-trifluoroacetate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
45%	Stage #1: 1,8-dihydroxy-3-(2-hydroxyethoxy)-6-methylanthracene-9,10-dione; (2S)-2-[(tert-butoxycarbonyl)amino]-2-phenylethanoic acid With dmap; dicyclohexyl-carbodiimide In dichloromethane at 0℃; Stage #2: With trifluoroacetic acid In dichloromethane for 2h;	General procedure A for preparation of compounds 3a-3z, 4a-4b, and 7a-7l General procedure: To a mixture of compound 2 (1.00mmol) in dry dichloromethane (20mL) were added various N-Boc-amino acids (1.20mmol), dicyclohexyl carbodiimide (DCC) (4.50 mmol) and 4-(N,N-dimethlyamino)pyridine (DMAP) (1.00 mmol) at 0 °C. After stirring about 30 min to 5 h at 0 °C, TLC analysis showedthe complete consumption of compound 2, and then the resulting mixture was added dropwise TFA (5 mL) at the same temperature and kept stirring for anther about 2 h. The insoluble side product was filtered out and the filtrate was evaporated to give the residue, which was purified by reversephase flash chromatography with the following conditions: Column: Spherical C18, 20-40 m, 330 g;Mobile Phase A: Water (plus 5 mM TFA); Mobile Phase B: ACN; Flow rate: 80 mL/min; Gradient: 5%B gradient in 10 min, 25% B-45% B gradient in 25 min; Detector: 254 nm. The fractions containing thedesired product were collected at around 40% B and concentrated under reduced pressure to affordcompounds 3a-3z in 20% to 50% yields.

Reference： [1]Yang, Kun; Jin, Ming-Ji; Quan, Zhe-Shan; Piao, Hu-Ri [Molecules, 2019, vol. 24, # 5]

64
[ 5830-31-9 ]
[ 2900-27-8 ]
tert-butyl ((S)-2-(((S)-1-(dimethylamino)-1-oxo-3-phenylpropan-2-yl)amino)- 2-oxo-1-phenylethyl)carbamate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
85%	With O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; N-ethyl-N,N-diisopropylamine In dichloromethane at 20℃; for 0.5h;	1.1.3 1.3 Preparation of compound a1-36 and a1-41 Compound 5 (N-(tert-butoxycarbonyl)-L-2-phenylglycine, 1.26g, 5.0mmol),Benzotriazole-N,N,N',N'-tetramethylurea hexafluorophosphate (HBTU, 2.09g, 5.5mmol),Compound 6 (N,N-dimethyl-L-phenylpropionamide, 821mg, 5.0mmol) was added to the reactor,Add 20mL of dichloromethane,Then add N,N-diisopropylethylamine (DIEA, 1.65mL, 10mmol),Stir at room temperature for half an hour to complete the reaction.Add a certain amount of water to quench the reaction,And repeatedly extract the water phase with DCM,The combined organic phase was dried with anhydrous Na2SO4,After filtering and spin-drying,The column was separated to obtain the substrate 1-36a.

Reference： [1]Current Patent Assignee: CHINESE ACADEMY OF SCIENCES - CN111302968, 2020, A Location in patent: Paragraph 0058-0063

65
[ 111-87-5 ]
[ 2900-27-8 ]
C₂₁H₃₃NO₄ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
90%	With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane; N,N-dimethyl-formamide at 20℃; for 24h;	7: 6 (1.33 g, 5.00 mmol), 1-octanol (0.78 ml, 5.00 mmol), EDC (1.15 g, 6.00 mmol) and DMAP (1.22 g, 10.0 mmol) were dissolved in CH2CI2/DMF (25 ruL:5 mL). The reaction mixture was stirred for 24 h at room temperature. Solvent was removed in vacuo and the crude product was dissolved in CH2CI2 (30 mL), and washed with water (2 x 40 mL) the crude product was purified by flash column chromatography (Hexane:EA = 8: 1, v:v) to give the target compound 7 as a white solid. Yield: 1.70 g, 90%. NMR (400 MHz, CDCL) d 7.31- 7.26 (m, 2H), 7.24 (dd, / = 5.2, 1.9 Hz, 1H), 7.13 (d, / = 6.8 Hz, 2H), 4.98 (d, / = 8.1 Hz, 1H), 4.57 (dd, / = 14.1, 6.1 Hz, 1H), 4.12 - 4.03 (m, 2H), 3.13 - 3.02 (m, 2H), 1.60 - 1.55 (m, 2H), 1.42 (s, 9H), 1.27 (s, 10H), 0.88 (d, 7 = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCL) d 172.03, 155.11, 136.11, 129.37, 128.53, 127.00, 65.58, 54.46, 38.47, 31.81, 29.20, 29.18, 28.49, 28.33, 25.85, 22.68, 14.14. MS-ESI: calculated for [M+Na]+ (C22H3s04NNa): m/z 400.28, found: m/z 400.37.

Reference： [1]Current Patent Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH - WO2020/159441, 2020, A1 Location in patent: Page/Page column 38; 45

66
[ 2900-27-8 ]
C₂₂H₂₅N₃O₃ [ No CAS ]
C₃₀H₃₂N₄O₄ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
90%	Stage #1: (2S)-2-[(tert-butoxycarbonyl)amino]-2-phenylethanoic acid; C₂₂H₂₅N₃O₃ With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In N,N-dimethyl-formamide at 20℃; for 0.5h; Stage #2: With trifluoroacetic acid	1 Intermediate 2 (n=l, R^13a= phenyl): HATU (13 mg, 0.033 mmol, 1.1 equiv.) was added to a solution of the amino acid compound L (8.5 mg, 0.033 mmol, 1.1 equiv.), compound M (15 mg, 0.03 mmol, 1 equiv.) and DIEA (0.03 mL, 0.18 mmol, 6 equiv.) in DMF (1.0 mL) and the resultant mixture was stirred at room temperature for 30 min. The crude product was purified by HPLC (MeCN/thO 50%-100%, 50 min, 60 mL/min, the product came out when MeCN is 61.3%). TFA was used to remove the Boc group to afford Intermediate 2 (14 mg, 90% yield).

Reference： [1]Current Patent Assignee: UNIVERSITY OF MICHIGAN - WO2020/205467, 2020, A1 Location in patent: Paragraph 0537; 0543; 0546

67
[ 2900-27-8 ]
C₂₄H₃₁N₃O₃ [ No CAS ]
C₃₂H₃₈N₄O₄ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
85%	Stage #1: (2S)-2-[(tert-butoxycarbonyl)amino]-2-phenylethanoic acid; C₂₄H₃₁N₃O₃ With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In N,N-dimethyl-formamide at 20℃; for 0.5h; Stage #2: With trifluoroacetic acid In dichloromethane	20 Compound M: HATU (104 mg, 0.27 mmol, 1.1 equiv.) was added to a solution of amino acid compound L (63 mg, 0.25 mmol, 1.0 equiv.), compound K (130 mg, 0.25 mmol, 1.0 equiv.) and DIEA (0.26 mL, 1.5 mmol, 6 equiv.) in DMF (1.5 mL) and the resultant mixture was stirred at room temperature for 30 min. The crude product was purified by HPLC (McCN/HiO 55%-100%, 45 min, 60 mL/min, the product came out when MeCN is 64.6%). TFA/DCM = 1/1 solution was used to remove the Boc group to afford compound M (115 mg, 85% yield).

Reference： [1]Current Patent Assignee: UNIVERSITY OF MICHIGAN - WO2020/205467, 2020, A1 Location in patent: Paragraph 0579; 0580

68
[ 2900-27-8 ]
[ 15532-75-9 ]
(S)-tert-butyl (2-oxo-1-phenyl-2-(4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)ethyl)carbamate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
87%	With dicyclohexyl-carbodiimide In dichloromethane at 20℃; for 4h;
82%	Stage #1: (2S)-2-[(tert-butoxycarbonyl)amino]-2-phenylethanoic acid With dicyclohexyl-carbodiimide In dichloromethane for 0.25h; Stage #2: 1-(3-Trifluoromethylphenyl)piperazine In dichloromethane at 20℃; for 4h;	4.1.1. synthetic procedure for Boc-protected compounds (R)-1-(R)-5 and(S)-1 General procedure: To a anhydrous DCM (20 mL) solution of (R) or (S)-2-((tert-butoxycarbonyl)amino)-2-phenylacetic acid (1.25 g, 5 mmol, 1 eq) was successivelyadded DCC (1.55 g, 7.5 mmol, 1.5 eq) dissolved in 5 mL ofanhydrous DCM. After stirring (15 min), the appropriate phenylpiperazine(5 mmol, 1.0 eq) dissolved in 5 mL of anhydrous DCM wasadded dropwise and the reaction was stirred at room temperature for 4h. The DCM was evaporated in vacuo, and the product purified by columnchromatography using a DCM:MeOH-9:0.5 (v/v) mixture as asolvent system.

Reference： [1]Abram, Michał; Jakubiec, Marcin; Kamiński, Krzysztof; Kamiński, Rafał M.; Latacz, Gniewomir; Mogilski, Szczepan; Nieoczym, Dorota; Rapacz, Anna; Socała, Katarzyna; Szafarz, Małgorzata; Szulczyk, Bartłomiej; Wlaź, Piotr; Wyska, Elżbieta [International Journal of Molecular Sciences, 2021, vol. 22, # 23]
[2]Abram, Michał; Rapacz, Anna; Latacz, Gniewomir; Szulczyk, Bartłomiej; Kalinowska-Tłuścik, Justyna; Otto-Ślusarczyk, Dagmara; Struga, Marta; Kamiński, Rafał M.; Kamiński, Krzysztof [Bioorganic Chemistry, 2021, vol. 109]

Purity	Size	Price	VIP Price	USA Stock *0-1 Day	Global Stock *5-7 Days	Quantity
{[ item.p_purity ]}	{[ item.pr_size ]}	{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]}	{[ getRatePrice(item.pr_usd, 1,1) ]}	{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]}	{[ item.pr_usastock ]}	Inquiry -	{[ item.pr_chinastock ]}	Inquiry -

CAS No. :	2900-27-8	MDL No. :	MFCD00065588
Formula :	C₁₃H₁₇NO₄	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	HOBFSNNENNQQIU-JTQLQIEISA-N
M.W :	251.28	Pubchem ID :	11010409
Synonyms :	Boc-Phg-OH

Num. heavy atoms :	18
Num. arom. heavy atoms :	6
Fraction Csp3 :	0.38
Num. rotatable bonds :	6
Num. H-bond acceptors :	4.0
Num. H-bond donors :	2.0
Molar Refractivity :	66.54
TPSA :	75.63 Å²

GI absorption :	High
BBB permeant :	Yes
P-gp substrate :	No
CYP1A2 inhibitor :	No
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-6.26 cm/s

Log Po/w (iLOGP) :	2.25
Log Po/w (XLOGP3) :	2.22
Log Po/w (WLOGP) :	2.01
Log Po/w (MLOGP) :	1.7
Log Po/w (SILICOS-IT) :	1.23
Consensus Log Po/w :	1.88

[ CAS No. 2900-27-8 ]

Quality Control of [ 2900-27-8 ]

Related Doc. of [ 2900-27-8 ]

Product Details of [ 2900-27-8 ]

Calculated chemistry of [ 2900-27-8 ]

Physicochemical Properties

Pharmacokinetics

Lipophilicity

Druglikeness

Water Solubility

Medicinal Chemistry

Safety of [ 2900-27-8 ]

Application In Synthesis of [ 2900-27-8 ]

[ 2900-27-8 ] Synthesis Path-Upstream 1~7

[ 2900-27-8 ] Synthesis Path-Downstream 1~68

Related Functional Groups of
[ 2900-27-8 ]

Amino Acid Derivatives

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	0.0
Bioavailability Score :	0.56

Log S (ESOL) :	-2.65
Solubility :	0.566 mg/ml ; 0.00225 mol/l
Class :	Soluble
Log S (Ali) :	-3.44
Solubility :	0.0906 mg/ml ; 0.00036 mol/l
Class :	Soluble
Log S (SILICOS-IT) :	-2.78
Solubility :	0.421 mg/ml ; 0.00167 mol/l
Class :	Soluble

PAINS :	0.0 alert
Brenk :	0.0 alert
Leadlikeness :	0.0
Synthetic accessibility :	2.53

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P261-P305+P351+P338	UN#:	N/A
Hazard Statements:	H315-H319-H335	Packing Group:	N/A
GHS Pictogram:

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

[ CAS No. 2900-27-8 ]

Quality Control of [ 2900-27-8 ]

Related Doc. of [ 2900-27-8 ]

Product Details of [ 2900-27-8 ]

Calculated chemistry of [ 2900-27-8 ]

Physicochemical Properties

Pharmacokinetics

Lipophilicity

Druglikeness

Water Solubility

Medicinal Chemistry

Safety of [ 2900-27-8 ]

Application In Synthesis of [ 2900-27-8 ]

[ 2900-27-8 ] Synthesis Path-Upstream 1~7

[ 2900-27-8 ] Synthesis Path-Downstream 1~68

Related Functional Groups of [ 2900-27-8 ]

Amino Acid Derivatives

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Related Functional Groups of
[ 2900-27-8 ]